Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)

Bugge C, Adams EJ, Gopinath D, Stewart F, Dembinsky M, Sobiesuo P, Kearney R

Bugge C, Adams EJ, Gopinath D, Stewart F, Dembinsky M, Sobiesuo P, Kearney R.
Pessaries (mechanical devices) for managing pelvic organ prolapse in women.
DOI: 10.1002/14651858.CD004010.pub4.

www.cochranelibrary.com
Analysis 1.1. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 1: Women’s perceived improvement in prolapse symptoms: POP score of Australian Pelvic Floor Questionnaire at 12 months (range 0-10, higher score = worse symptoms) ........................................................................................................... 36

Analysis 1.2. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 2: Site-specific grading of prolapse - anterior - (measured with POP-Q) at 12 months ........................................................................................................... 36

Analysis 1.3. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 3: Site-specific grading of prolapse - posterior - (measured with POP-Q) at 12 months ........................................................................................................... 36

Analysis 1.4. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 4: Cure or improvement of bladder problems at 12 months (measured with bladder score of Australian Pelvic Floor Questionnaire, range 0-10, higher score = worse symptoms) ........................................................................................................... 36

Analysis 1.5. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 5: Cure or improvement of bowel problems at 12 months (measured with bowel score of Australian Pelvic Floor Questionnaire, range 0-10, higher score = worse symptoms) ........................................................................................................... 37

Analysis 1.6. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 6: Cure or improvement of sexual problems at 12 months (measured with sex score of Australian Pelvic Floor Questionnaire, range 0-10, higher score = worse symptoms) ........................................................................................................... 37

Analysis 2.1. Comparison 2: Any pessary versus PFMT, Outcome 1: Women’s perceived improvement of prolapse symptoms at 12 months (measured with PFDI-20; range: 0-300, higher score = worse symptoms) ........................................................................................................... 38

Analysis 2.2. Comparison 2: Any pessary versus PFMT, Outcome 2: Women’s perceived improvement of prolapse symptoms at 24 months (measured with PFDI-20; range: 0-300, higher score = worse symptoms) ........................................................................................................... 39

Analysis 2.3. Comparison 2: Any pessary versus PFMT, Outcome 3: Women’s perceived improvement of prolapse symptoms at 12 months (measured with POPDI-6; range: 0-100, higher score = worse symptoms) ........................................................................................................... 39

Analysis 2.4. Comparison 2: Any pessary versus PFMT, Outcome 4: Women’s perceived improvement of prolapse symptoms at 24 months (POPDI-6; range: 0-100, higher score = worse symptoms) ........................................................................................................... 39

Analysis 2.5. Comparison 2: Any pessary versus PFMT, Outcome 5: Women’s perceived improvement of prolapse symptoms at 24 months ........................................................................................................... 39

Analysis 2.6. Comparison 2: Any pessary versus PFMT, Outcome 6: Prolapse-specific quality of life at 12 months (measured with PFQI-7, range: 0-300, higher score = worse QoL) ........................................................................................................... 40

Analysis 2.7. Comparison 2: Any pessary versus PFMT, Outcome 7: Prolapse-specific quality of life at 24 months (measured with PFQI-7, range: 0-300, higher score = worse QoL) ........................................................................................................... 40

Analysis 2.8. Comparison 2: Any pessary versus PFMT, Outcome 8: Quality of life at 12 months (measured with PCS-12, range: 0-100, higher score = better health status) ........................................................................................................... 40

Analysis 2.9. Comparison 2: Any pessary versus PFMT, Outcome 9: Quality of life at 24 months (measures with PCS-12, range: 0-100, higher score = better health status) ........................................................................................................... 40

Analysis 2.10. Comparison 2: Any pessary versus PFMT, Outcome 10: Quality of life at 12 months (measured with MCS-12, range: 0-100, higher score = better health status) ........................................................................................................... 41
Analysis 2.11. Comparison 2: Any pessary versus PFMT, Outcome 11: Quality of life at 24 months (measured with MCS-12, range: 0-100, higher score = better health status) .......................................................... 41
Analysis 2.12. Comparison 2: Any pessary versus PFMT, Outcome 12: Cure or improvement of bladder problems at 12 months (measured with UDI-6, range: 0-100, higher score = worse symptoms) ........................................................................................................................................ 41
Analysis 2.13. Comparison 2: Any pessary versus PFMT, Outcome 13: Cure or improvement of bladder problems at 24 months (measured with UDI-6, range: 0-100, higher score = worse symptoms) ........................................................................................................................................ 41
Analysis 2.14. Comparison 2: Any pessary versus PFMT, Outcome 14: Cure or improvement of bowel problems at 12 months (measured with CRADI-8, range: 0-100, higher score = worse symptoms) ........................................................................................................................................ 42
Analysis 2.15. Comparison 2: Any pessary versus PFMT, Outcome 15: Cure or improvement of bowel problems at 24 months (measured with CRADI-8, range: 0-100, higher score = worse symptoms) ........................................................................................................................................ 42
Analysis 2.16. Comparison 2: Any pessary versus PFMT, Outcome 16: Cure or improvement of bowel problems at 24 months (measured with PISQ-12, range: 0-48, higher score = better sexual functioning) ........................................................................................................................................ 42
Analysis 2.17. Comparison 2: Any pessary versus PFMT, Outcome 17: Cure or improvement of sexual problems at 24 months (measured with PISQ-12, range: 0-48, higher score = better sexual functioning) ........................................................................................................................................ 42
Analysis 2.18. Comparison 2: Any pessary versus PFMT, Outcome 18: Number of women with adverse events ................................................ 43
Analysis 3.1. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 1: Perceived improvement of prolapse symptoms at 12 months ........................................................................................................................................ 43
Analysis 3.2. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 2: Cure or improvement of bladder problems - SUI ........................................................................................................................................ 44
Analysis 3.3. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 3: Cure or improvement of bladder problems - UUI ........................................................................................................................................ 44
Analysis 3.4. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 4: Cure or improvement of bladder problems - voiding difficulty ........................................................................................................................................ 44
Analysis 3.5. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 5: Number of women with adverse events - abnormal vaginal bleeding ........................................................................................................................................ 44
Analysis 3.6. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 6: Number of women with adverse events - de novo voiding difficulty ........................................................................................................................................ 45
APPENDICES ........................................................................................................................................................................................................ 45
WHAT'S NEW ........................................................................................................................................................................................................ 45
HISTORY ............................................................................................................................................................................................................... 51
CONTRIBUTIONS OF AUTHORS ................................................................................................................................................................. 52
DECLARATIONS OF INTEREST ..................................................................................................................................................................... 53
SOURCES OF SUPPORT ................................................................................................................................................................................. 53
DIFFERENCES BETWEEN PROTOCOL AND REVIEW ........................................................................................................................................ 53
INDEX TERMS ........................................................................................................................................................................................................ 53
Pessaries (mechanical devices) for managing pelvic organ prolapse in women

Background
Pelvic organ prolapse is a common problem in women. About 40% of women will experience prolapse in their lifetime, with the proportion expected to rise in line with an ageing population. Women experience a variety of troublesome symptoms as a consequence of prolapse, including a feeling of ‘something coming down’ into the vagina, pain, urinary symptoms, bowel symptoms and sexual difficulties. Treatment for prolapse includes surgery, pelvic floor muscle training (PFMT) and vaginal pessaries. Vaginal pessaries are passive mechanical devices designed to support the vagina and hold the prolapsed organs back in the anatomically correct position. The most commonly used pessaries are made from polyvinyl-chloride, polythene, silicone or latex. Pessaries are frequently used by clinicians with high numbers of clinicians offering a pessary as first-line treatment for prolapse.

This is an update of a Cochrane Review first published in 2003 and last published in 2013.

Objectives
To assess the effects of pessaries (mechanical devices) for managing pelvic organ prolapse in women; and summarise the principal findings of relevant economic evaluations of this intervention.

Search methods
We searched the Cochrane Incontinence Specialised Register which contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO ICTRP and handsearching of journals and conference proceedings (searched 28 January 2020). We searched the reference lists of relevant articles and contacted the authors of included studies.

Selection criteria
We included randomised and quasi-randomised controlled trials which included a pessary for pelvic organ prolapse in at least one arm of the study.
Data collection and analysis
Two review authors independently assessed abstracts, extracted data, assessed risk of bias and carried out GRADE assessments with arbitration from a third review author if necessary.

Main results
We included four studies involving a total of 478 women with various stages of prolapse, all of which took place in high-income countries. In one trial, only six of the 113 recruited women consented to random assignment to an intervention and no data are available for those six women. We could not perform any meta-analysis because each of the trials addressed a different comparison. None of the trials reported data about perceived resolution of prolapse symptoms or about psychological outcome measures. All studies reported data about perceived improvement of prolapse symptoms.

Generally, the trials were at high risk of performance bias, due to lack of blinding, and low risk of selection bias. We downgraded the certainty of evidence for imprecision resulting from the low numbers of women participating in the trials.

Pessary versus no treatment: at 12 months’ follow-up, we are uncertain about the effect of pessaries compared with no treatment on perceived improvement of prolapse symptoms (mean difference (MD) in questionnaire scores -0.03, 95% confidence interval (CI) -0.61 to 0.55; 27 women; 1 study; very low-certainty evidence), and cure or improvement of sexual problems (MD -0.29, 95% CI -1.67 to 1.09; 27 women; 1 study; very low-certainty evidence). In this comparison we did not find any evidence relating to prolapse-specific quality of life or to the number of women experiencing adverse events (abnormal vaginal bleeding or de novo voiding difficulty).

Pessary versus pelvic floor muscle training (PFMT): at 12 months’ follow-up, we are uncertain if there is a difference between pessaries and PFMT in terms of women’s perceived improvement in prolapse symptoms (MD -9.60, 95% CI -22.53 to 3.33; 137 women; low-certainty evidence), prolapse-specific quality of life (MD -3.30, 95% CI -8.70 to 15.30; 1 study; 116 women; low-certainty evidence), or cure or improvement of sexual problems (MD -2.30, 95% -5.20 to 0.60; 1 study; 48 women; low-certainty evidence). Pessaries may result in a large increase in risk of adverse events compared with PFMT (RR 75.25, 95% CI 4.70 to 1205.45; 1 study; 97 women; low-certainty evidence). Adverse events included increased vaginal discharge, and/or increased urinary incontinence and/or erosion or irritation of the vaginal walls.

Pessary plus PFMT versus PFMT alone: at 12 months’ follow-up, pessary plus PFMT probably leads to more women perceiving improvement in their prolapse symptoms compared with PFMT alone (RR 2.15, 95% CI 1.58 to 2.94; 1 study; 260 women; moderate-certainty evidence). At 12 months’ follow-up, pessary plus PFMT probably improves women’s prolapse-specific quality of life compared with PFMT alone (median (interquartile range (IQR)) PO PIQ score: pessary plus PFMT 0.3 (0 to 22.2); 132 women; PFMT only 8.9 (0 to 64.9); 128 women; P = 0.02; moderate-certainty evidence). Pessary plus PFMT may slightly increase the risk of abnormal vaginal bleeding compared with PFMT alone (RR 2.18, 95% CI 0.69 to 6.91; 1 study; 260 women; low-certainty evidence). The evidence is uncertain if pessary plus PFMT has any effect on the risk of de novo voiding difficulty compared with PFMT alone (RR 1.32, 95% CI 0.54 to 3.19; 1 study; 189 women; low-certainty evidence).

Authors’ conclusions
We are uncertain if pessaries improve pelvic organ prolapse symptoms for women compared with no treatment or PFMT but pessaries in addition to PFMT probably improve women’s pelvic organ prolapse symptoms and prolapse-specific quality of life. However, there may be an increased risk of adverse events with pessaries compared to PFMT. Future trials should recruit adequate numbers of women and measure clinically important outcomes such as prolapse specific quality of life and resolution of prolapse symptoms.

The review found two relevant economic evaluations. Of these, one assessed the cost-effectiveness of pessary treatment, expectant management and surgical procedures, and the other compared pessary treatment to PFMT.

PLAIN LANGUAGE SUMMARY

Pessaries (mechanical devices) for managing pelvic organ prolapse in women

Review question
How effective are pessaries (mechanical devices) for managing pelvic organ prolapse in women?

Background
Pelvic organs, such as the uterus, bladder or bowel, may protrude into the vagina because of weakness in the tissues that normally support them. This protrusion is known as pelvic organ prolapse. Women who experience prolapse report a wide variety of symptoms that affect their quality of life. The choice of treatment options for pelvic organ prolapse symptoms is dictated largely by patient choice, as the interventions of lifestyle changes, pelvic floor muscle training (PFMT), pessary and surgery are very different with different complication risks. Vaginal pessaries are one treatment option for prolapse that are commonly used to restore the prolapsed organs to their normal position and hence relieve symptoms. A vaginal pessary can be used to treat all four prolapse stages.
How up-to-date is this review?

We searched for studies published up to 28 January 2020.

Study characteristics

We found four studies involving 478 women with various stages of prolapse. All four studies were carried out in high-income countries.

Key results

None of the studies reported whether or not the women’s prolapse symptoms were completely resolved. We are uncertain about the effect of pessaries compared with no treatment on perceived improvement of prolapse symptoms, and cure or improvement of sexual problems. We did not find any evidence relating to the risk of vaginal bleeding or difficulty urinating in the studies comparing pessaries with no treatment.

We are uncertain if pessaries have any effect on improving women’s prolapse symptoms when pessary is compared with PFMT. The evidence is also very uncertain about the effect of pessaries compared with PFMT on prolapse-specific quality of life and on sexual problems. Pessaries may result in a greater risk of adverse events, including vaginal discharge, increased urinary incontinence and erosion of the vaginal walls, compared with PFMT.

Pessary plus PFMT probably leads to more women perceiving improvement in their prolapse symptoms and in their prolapse-specific quality of life compared with PFMT alone. Compared with PFMT alone, pessary plus PFMT may slightly increase the risk of abnormal vaginal bleeding and the risk of having difficulty urinating, for women who did not have this problem before starting prolapse treatment, but the evidence is very uncertain.

Certainty of the evidence

We assessed the evidence relating to pessary compared with no treatment as very low certainty because of the low numbers of women participating in the study and because of problems with the way the trial was conducted. We assessed the evidence relating to pessary compared with PFMT, and pessary plus PFMT compared with PFMT alone, as low- to moderate-certainty because of the low numbers of women involved in the studies.

Authors' conclusions

Each of these trials contain small numbers of women, reducing the certainty of our conclusions. We are uncertain if pessaries improve pelvic organ prolapse symptoms for women compared with no treatment or when compared to another active treatment like PFMT, but pessaries in addition to PFMT probably improve women’s symptoms and prolapse-specific quality of life. However, there may be an increased risk of adverse events with pessaries compared to no treatment or PFMT.

The review found two economic evaluation studies that compared pessary treatment to alternative interventions (PFMT, expectant management and surgical procedures).
### Summary of findings 1. Any pessary compared to control, waiting list or no active treatment

#### Any pessary compared to standard care

**Patient or population:** pelvic organ prolapse in women  
**Setting:** urogynaecological clinic  
**Intervention:** any pessary  
**Comparison:** standard care

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perceived resolution of prolapse symptoms: ≥ 12 months</td>
<td>Not reported</td>
<td></td>
<td></td>
<td>VERY LOW 1 2</td>
<td></td>
</tr>
<tr>
<td>Perceived improvement of prolapse symptoms (higher score = worse symptoms) assessed with: POP score of Australian Pelvic Floor Questionnaire range: 0-10 Follow-up: 12 months</td>
<td>The mean score in the comparator group was 0.31 MD 0.03 lower (0.61 lower to 0.55 higher)</td>
<td>-</td>
<td>27 (1 RCT)</td>
<td>⊕⊝⊝⊝ VERY LOW 1 2</td>
<td></td>
</tr>
<tr>
<td>Prolapse-specific quality of life ≥ 12 months</td>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cure or improvement of sexual problems assessed with: sex score of the Australian Pelvic Floor Questionnaire score: 0-10 (higher score = worse symptoms) Follow-up: 12 months</td>
<td>The mean score in the comparator group was 1.45 MD 0.29 lower (1.67 lower to 1.09 higher)</td>
<td>-</td>
<td>27 (1 RCT)</td>
<td>⊕⊝⊝⊝ VERY LOW 1 2</td>
<td></td>
</tr>
<tr>
<td>Psychological outcome measures at ≥ 12 months</td>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of women with adverse events (vaginal bleeding, voiding difficulty)</td>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; MD: mean difference; POP: pelvic organ prolapse; RCT: randomised controlled trial.

**GRADE Working Group grades of evidence**

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

1 Downgraded one level for risk of bias (performance and attrition bias)
2 Downgraded two levels for imprecision (few participants and wide 95% CI crossing the line of no effect)

## Summary of findings 2. Any pessary compared to pelvic floor muscle training (PFMT) for pelvic organ prolapse in women

### Any pessary compared to PFMT or pelvic organ prolapse in women

**Patient or population:** pelvic organ prolapse in women  
**Setting:** urogynaecological clinic  
**Intervention:** any pessary  
**Comparison:** PFMT

### Outcomes

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perceived resolution of prolapse symptoms ≥ 12 months</td>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Women’s perceived improvement of prolapse symptoms (higher score = worse symptoms) assessed with: POPDI-6  
  Scale from: 0 to 100  
  Follow-up: 12 months                                                    | The mean POPDI-6 score in the PFMT group was 16.4  
  MD 3.60 lower (8.73 lower to 1.53 higher)                                | -                     | 117 (1 RCT)                  | ◐◑◐◑ LOW 1                       |          |
| Prolapse-specific quality of life (higher score = worse QoL)  
  assessed with: PFIQ-7  
  Scale from: 0 to 300  
  Follow-up: 12 months                                                    | The mean PFIQ-7 score in the PFMT group was 15.8  
  MD 3.3 higher (8.70 lower to 15.30 higher)                               | -                     | 116 (1 RCT)                  | ◐◑◐◑ LOW 1                       |          |
| Cure or improvement of sexual problems (higher score = better sexual functioning)  
  assessed with: PISQ-12,  
  Scale from: 0 to 48  
  Follow-up: 12 months                                                    | The mean PISQ-12 score in the PFMT group was 37.6  
  MD 2.30 lower (5.20 lower to 0.60 higher)                                | -                     | 48 (1 RCT)                   | ◐◑◐◑ LOW 1                       |          |
Psychological outcome measures at ≥ 12 months  

<table>
<thead>
<tr>
<th>Number of women with adverse events</th>
<th>21/35 women in pessary group and 0/62 women in PFMT group experienced adverse events (14 increased vaginal discharge, 5 increased urinary incontinence, 10 erosion or irritation of the vaginal walls).</th>
</tr>
</thead>
</table>

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: Confidence interval; MD: mean difference; PFIQ: Pelvic Floor Impact Questionnaire; PISQ: Prolapse/Urinary Incontinence Sexual Questionnaire; POPDI-6: Pelvic Organ Prolapse Distress Inventory 6; QI: quality of life; RCT: randomised controlled trial; RR: Risk ratio.

**GRADE Working Group grades of evidence**  
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.  
Moderate certainty: We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.  
Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.  
Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.  

1 Downgraded two levels due to imprecision: few participants and wide 95% CI, consistent with possible benefit and possible harm  
2 Downgraded two levels due to imprecision: few participants and few events, and the 95% CI suggests event rates that are implausibly wide

**Summary of findings 3. Pessary plus PFMT compared to pelvic floor muscle training (PFMT) alone for pelvic organ prolapse in women**

<table>
<thead>
<tr>
<th>Patient or population: pelvic organ prolapse in women</th>
<th>Setting: urogynaecological clinic</th>
<th>Intervention: pessary plus PFMT</th>
<th>Comparison: PFMT alone</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>Nº of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perceived resolution of prolapse symptoms ≥ 12 months</td>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Perceived improvement of prolapse symptoms

**Follow-up: 12 months**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Perceived Improvement</th>
<th>RR (95% CI)</th>
<th>Study Count</th>
<th>GRADE</th>
<th>certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pessary + PFMT (246 women)</td>
<td>605 per 1000 (444 to 827)</td>
<td>RR 2.15 (1.58 to 2.94)</td>
<td>260 (1 RCT)</td>
<td>MODERATE 1</td>
<td><strong>⊕⊕⊝</strong></td>
</tr>
<tr>
<td>PFMT (233 women)</td>
<td>281 per 1000</td>
<td>-</td>
<td>260 (1 RCT)</td>
<td>MODERATE 1</td>
<td><strong>⊕⊕⊝</strong></td>
</tr>
</tbody>
</table>

### Prolapse-specific quality of life

Assessed with: POPIQ (higher score = worse quality of life) (scale: 0-100)

**Follow-up: 12 months**

<table>
<thead>
<tr>
<th>Group</th>
<th>Median (IQR) scores</th>
<th>RR (95% CI)</th>
<th>Study Count</th>
<th>GRADE</th>
<th>certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pessary + PFMT (132 women)</td>
<td>Pessary + PFMT = 0.3 (0-22.2)</td>
<td>RR 2.18 (0.69 to 6.91)</td>
<td>260 (1 RCT)</td>
<td>LOW 2</td>
<td><strong>⊕⊕⊥</strong></td>
</tr>
<tr>
<td>PFMT (128 women)</td>
<td>PFMT = 8.9 (0–64.9)</td>
<td>-</td>
<td>260 (1 RCT)</td>
<td>MODERATE 1</td>
<td><strong>⊕⊕⊝</strong></td>
</tr>
</tbody>
</table>

### Cure or improvement of sexual problems ≥ 12 months

Not reported

### Psychological outcome measures at ≥ 12 months

Not reported

### Number of women with adverse events - abnormal vaginal bleeding

**Follow-up: 12 months**

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of women</th>
<th>Per 1000</th>
<th>RR (95% CI)</th>
<th>Study Count</th>
<th>GRADE</th>
<th>certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pessary + PFMT (132 women)</td>
<td>31 per 1000</td>
<td>22 to 216</td>
<td>RR 2.18 (0.69 to 6.91)</td>
<td>260 (1 RCT)</td>
<td>LOW 2</td>
<td><strong>⊕⊕⊥</strong></td>
</tr>
<tr>
<td>PFMT (128 women)</td>
<td>68 per 1000</td>
<td>0.69 to 6.91</td>
<td>-</td>
<td>260 (1 RCT)</td>
<td>MODERATE 1</td>
<td><strong>⊕⊕⊝</strong></td>
</tr>
</tbody>
</table>

### Number of women with adverse events - de novo voiding difficulty

**Follow-up: 12 months**

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of women</th>
<th>Per 1000</th>
<th>RR (95% CI)</th>
<th>Study Count</th>
<th>GRADE</th>
<th>certainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pessary + PFMT (132 women)</td>
<td>82 per 1000</td>
<td>45 to 263</td>
<td>RR 1.32 (0.54 to 3.19)</td>
<td>189 (1 RCT)</td>
<td>LOW 2</td>
<td><strong>⊕⊕⊥</strong></td>
</tr>
<tr>
<td>PFMT (128 women)</td>
<td>109 per 1000</td>
<td>0.54 to 3.19</td>
<td>-</td>
<td>189 (1 RCT)</td>
<td>MODERATE 1</td>
<td><strong>⊕⊕⊝</strong></td>
</tr>
</tbody>
</table>

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

**CI:** Confidence interval; **POPIQ:** Pelvic Organ Prolapse Impact Questionnaire; **RCT:** randomised controlled trial; **RR:** Risk ratio.

**GRADE Working Group grades of evidence**

**High certainty:** we are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.

**Very low certainty:** we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect.

1 Downgraded one level for imprecision: few participants

2 Downgraded two levels for imprecision: few participants and wide 95% CI spanning possible harm and possible benefit
BACKGROUND

Description of the condition

Pelvic organ prolapse is the descent of some part, or parts, of the female pelvic organs (uterus, bladder and rectum) from their normal anatomical position into the vagina. It affects about 40% of women aged over 40 (Hendrix 2002), with the prevalence expected to increase as the population ages (Wu 2011). Pelvic organ prolapse includes anterior vaginal wall prolapse (cystocele, urethrococoele), posterior vaginal wall prolapse (enterocele, rectocele, perineal deficiency), and uterine or vaginal vault prolapse. Women can present with prolapse in one or more of these sites. The International Continence Society has standardised the naming of the condition using the POP-Q (Pelvic Organ Prolapse Quantification) evaluation (Bump 1996), but in this review we have also used the descriptive terms above as these are compatible with literature searches.

The cause of pelvic organ prolapse is complex and multifactorial. Various risk factors have been proposed, including pregnancy, childbirth, hereditary factors, denervation or weakness of the pelvic floor, ageing, menopause, and factors associated with chronically raised intra-abdominal pressure (such as obesity, coughing and heavy lifting) (Bump 1998; Dietz 2008; Gyhagen 2015; Jelovsek 2018; MacLennan 2000).

Women with prolapse may have a variety of pelvic floor symptoms (Barber 2001; Hagen 2009; Jelovsek 2006; Lone 2011). Women experience symptoms of ‘something coming down’, pelvic heaviness, a dragging sensation in the vagina, a bulge, lump or protrusion coming down from the vagina and backache. Women can also experience symptoms related to the movement of the pelvic organs and their protrusion into the vagina, which include urinary symptoms, bowel symptoms and sexual difficulties. Symptoms, and perceived bother of symptoms, may negatively affect a woman’s body image, quality of life and mental health, as well as their ability to perform day to day activities (Jelovsek 2006; Lowder 2011; Pakbaz 2010).

Description of the intervention

Prolapse treatment may be dependent on a number of factors, including severity of prolapse, the bother of the associated symptoms, the woman’s general health and the woman’s treatment preference (Basu 2011; Kapoor 2009). Various treatment options exist for women who have pelvic organ prolapse and these can be split into surgical and conservative options. Approximately 9.5% of women will undergo prolapse surgery in their lifetime (Abdel-Fattah 2011). A US-based study forecast that approximately 9.2 million women will be affected by pelvic organ prolapse by 2050 (Wu 2009), and about 300,000 women undergo pelvic organ prolapse surgery in the USA every year costing over 1 billion US dollars (the cost year was unclear) (Enemchukwu 2019; Subak 2001). The NHS spent over £45 million on the treatment of prolapse between 2017 and 2018 (Primary Care Women’s Health Forum 2019).

Vaginal pessaries are passive mechanical devices that are worn internally and designed to support the vaginal walls and apex. An extensive range of pessaries have been described for treating prolapse (Oliver 2011; Poma 2000). These consist mainly of PVC, latex or silicone pessaries, which are shaped devices inserted into and left inside the vagina to support the prolapsed pelvic organs. Two main groups of pessaries are used: support pessaries (e.g. ring pessary or ring pessary with support) and space filling pessaries (e.g. Gelhorn or cube) (Dwyer 2019; Oliver 2011). Support pessaries are inserted into the vagina and are positioned between the pubic bone and posterior vaginal fornix, providing support to descending organs. They do not prohibit vaginal intercourse and are easier to remove and replace. Space filling pessaries provide support by filling the vaginal space to prevent prolapse descent, creating a suction effect around the pessary which thereby increases the likelihood of retention. They are not compatible with vaginal intercourse and are more difficult to remove and replace (Dwyer 2019). Studies suggest that ring pessaries are the most commonly used in practice (Bugg 2013a; Cundiff 2000).

Recently published NICE guidance suggests considering pessary treatment (alone or with: pelvic floor muscle training (PFMT)) when women have symptomatic prolapse (NICE 2019). Surveys suggest that 87% to 98% of clinicians report using pessaries in their clinical practice (Bugg 2013a; Cundiff 2000; Gorti 2009; Pott-Grinstein 2001), while 77% of gynaecologists report using pessaries as a first-line treatment for prolapse (Cundiff 2000). Health professionals (87.6%) report that they are most likely to fit pessaries in women aged 60 or older and 98.8% would use a pessary for treatment when a woman is unfit for surgery (Bugg 2013a). Evidence from observational studies suggests that about 76% of women who try a pessary continue to use it for at least four weeks and, of those women who continue pessary use for more than four weeks, 86% continued to use the pessary for over five years (Lone 2011). Furthermore, observational studies have shown that pessaries may improve symptoms for women (Lamers 2011; Manchana 2012).

How the intervention might work

Pessaries are used in pelvic organ prolapse in order to physically support the vaginal walls and the pelvic organs behind them. The pessary is inserted into the vagina with a view to holding the prolapsed organs, supporting the pelvic structures, and relieving pressure on the bladder and bowel (Dumoulin 2017). Using a pessary in the management of pelvic organ prolapse aims to prevent the prolapse from becoming worse, as well as helping to decrease the frequency or severity of symptoms of prolapse, and averting or delaying the need for surgery (Oliver 2011).

Why it is important to do this review

The effectiveness of surgical treatment options for prolapse are reported in other Cochrane Reviews (Baessler 2018; Maher 2016a; Maher 2016b; Maher 2016c; Mowat 2018). Conservative treatment options that are currently used are pelvic floor muscle training (PFMT), vaginal pessaries and lifestyle advice. The effectiveness of PFMT and lifestyle advice is reported in one review (Hagen 2011a). The remaining conservative option, vaginal pessaries, is the focus of this review.

The majority of evidence for the use of pessaries comes from non-randomised studies (e.g. Brazell 2014; Clemons 2004b; Clemons 2004a; Clemons 2004c; Hanson 2006; Kapoor 2009; Lamers 2011; Lone 2011; Manchana 2012). As such, the effectiveness of pessaries for managing pelvic organ prolapse still needs to be clearly established. There is a lack of consensus as to the optimal treatment for women. Provided that sufficient numbers of trials of adequate quality have been conducted, the most reliable evidence
is likely to come from consideration of randomised controlled trials (RCTs), which is the basis for the current review. The aim is to help identify optimal practice and highlight where there is a need for further research.

Given that different costs are associated with the alternative interventions included in this review, it is important to conduct a brief economic commentary (BEC) to find available evidence (if any) on the costs of the interventions relative to their effectiveness.

**OBJECTIVES**

To assess the effects of pessaries (mechanical devices) for managing pelvic organ prolapse in women; and summarise the principal findings of relevant economic evaluations of this intervention.

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**

We included randomised trials (RCTs) and quasi-randomised trials in which at least one arm was a pessary for pelvic organ prolapse. We excluded cross-over studies.

**Types of participants**

We included studies focusing on adult women who were seeking treatment for pelvic organ prolapse. Participants could have prolapse with any POP-Q staging (Bump 1996), and prolapse of any type: anterior vaginal wall prolapse (cystocele, urethrocele); posterior vaginal wall prolapse (enterocoele, rectocoele, perineal deficiency); and uterine or vaginal vault prolapse. We included trials where women were seeking treatment for urinary incontinence (UI) or prolapse if the data for women with prolapse (including women with prolapse and UI) were considered, or available separately.

**Types of interventions**

We included studies where one arm involved allocation to a pessary aiming to provide support for pelvic organ prolapse. Thus, we excluded studies where the pessary was used for exercise (and not support) or where pessaries were only used to deliver drug treatments (such as oestrogen). Pessaries could be of any type and made of any material. The types of devices included support pessaries (e.g. ring, ring with support) and space-filling devices (e.g. shelf, Gelhorn, cube).

We considered the following comparisons and planned to present 'Summary of findings' tables for the first three.

- Any pessary versus control, waiting list or no active treatment.
- Any pessary versus another treatment (lifestyle interventions, oestrogen treatment, physical interventions such as pelvic floor muscle training, surgery).
- Any pessary plus another treatment versus the other treatment alone.
- One pessary versus another pessary.

**Types of outcome measures**

**Primary outcomes**

- Women’s perceived resolution of prolapse symptoms
- Women’s perceived improvement in prolapse symptoms (assessed using validated symptom questionnaires such as the Pelvic Floor Disability Index (PFDI) (Barber 2001; Barber 2005), or the Pelvic Organ Symptom Score (POP-SS) (Hagen 2009))

**Secondary outcomes**

- Patient-reported satisfaction with pessary treatment
- Grade of prolapse (i.e. the compartment that has the most descent, e.g. using Pelvic Organ Prolapse-Quantification (POP-Q) classification (Bump 1996))
- Site-specific grading of prolapse (i.e. the descent in each of the specific anterior, apical or posterior compartments, e.g. using POP-Q (Bump 1996))
- Prolapse-specific quality of life (measured with validated instrument, e.g. the Pelvic Floor Impact Questionnaire (PFIQ), Barber 2001; Barber 2005)
- Quality of life measured with generic quality of life or health status measures (e.g. SF-36, Ware 1993)
- Psychological outcome measures (e.g. Hospital Anxiety and Depression Scale (HADS), Zigmond 1983)
- Cure or improvement of bladder problems (including urinary incontinence, occult incontinence and relief of voiding difficulty)
- Cure or improvement of bowel problems (including relief of obstructed defecation)
- Cure or improvement of sexual problems (including acceptability of device to both partners)
- Number of women with adverse events (vaginal bleeding, voiding difficulty)

**Timing of outcome assessment**

We considered all outcomes at ≥ 12 months.

**Main outcomes for ‘Summary of findings’ tables**

These outcomes have been informed by a recent priority-setting exercise for pessary use (Lough 2018).

- Woman’s perceived resolution of prolapse symptoms at ≥ 12 months
- Woman’s perceived improvement in prolapse symptoms assessed using a validated symptom questionnaire at ≥ 12 months
- Prolapse-specific quality of life (e.g. PFIQ) at ≥ 12 months
- Cure or improvement of sexual problems at ≥ 12 months
- Psychological outcome measures at ≥ 12 months
- Number of women with adverse events (vaginal bleeding, voiding difficulty)

**Search methods for identification of studies**

We did not impose any language or other restrictions on any of the searches detailed below.
Electronic searches

Search for clinical effectiveness studies

We identified relevant trials from the Cochrane Incontinence Specialised Register. For more details of the search methods used to build the Specialised Register, please see the Group’s webpages where details of the Register’s development (from inception) and the most recent searches performed to populate the Register can be found. To summarise, the Register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, MEDLINE Epub Ahead of Print, ClinicalTrials.gov, WHO ITRP, Be Part of Research and handsearching of journals and conference proceedings. Many of the trials in the Cochrane Incontinence Specialised Register are also contained in CENTRAL.

The terms used to search the Cochrane Incontinence Group Specialised Register are given in Appendix 1. The date of the most recent search of the Register for this review: 28 January 2020.

The search methods and strategies used for some of the previous versions of this review are given in Appendix 2.

Search for economic evaluations

We performed additional searches for the brief economic commentary (BEC). We searched the following.

- The NHS Economic Evaluation Database (NHS EED) on the Centre for Reviews and Dissemination (CRD) website (covering from the earliest record in NHS EED, dating from 1968, up to and including 31 December 2014 when their coverage ended). Date of search: 13 February 2020.

As NHS EED is no longer actively updated, we performed additional searches of the following databases to identify eligible studies added to these databases from 1 January 2015 onwards (date of search: 13 February 2020):

- MEDLINE on OvidSP (covering 1 January 1946 to January February 1 2020); and
- Embase (on OvidSP) (covering 1 January 1974 to 2020 Week 06).

Details of the searches that were performed can be found in Appendix 3.

Searching other resources

We searched the reference lists of relevant articles for other possibly relevant trials. We also contacted the authors of included abstracts.

Data collection and analysis

We conducted data collection and analysis in accordance with methods specified in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2019).

Selection of studies

Two review authors independently screened all potentially eligible abstracts from the search (CB and DG or MD). We nominated a third review author to arbitrate in the event of disagreement (EJA). We excluded any studies which were not relevant at this stage. We then obtained the full-text articles of relevant studies. If there was any uncertainty on the eligibility of the studies based on title and abstract, we obtained the full paper, which was reviewed by the same two review authors.

Data extraction and management

Two review authors independently undertook data extraction using a predefined data extraction form (from CB, RK and FS). We then made comparisons to ensure accuracy. We resolved any discrepancies by discussion with, or referral to, a third party (EJA).

Assessment of risk of bias in included studies

We assessed the risk of bias within studies as part of the data extraction. We used the methods outlined in the Cochrane Handbook to assess risk of bias in the following domains (Higgins 2011): random sequence generation (selection bias); allocation concealment (selection bias); blinding of participants and personnel (detection bias); blinding of outcome assessors (performance bias); incomplete outcome data (attrition bias); selective reporting (reporting bias); other bias not considered under other domains. Two review authors assessed the included studies for risk of bias and any discrepancies were resolved by discussion and referred to a third author where necessary.

Measures of treatment effect

For binary outcomes, we have reported risk ratios (RR) and 95% confidence intervals (CI). For continuous outcomes, we reported mean differences (MDs) with 95% CIs.

Unit of analysis issues

The primary analysis was per woman randomised. Had data allowed, we would have analysed each pair of arms in multi-arm studies as a separate comparison. To avoid double-counting where the same study with three treatment arms is included twice in the same meta-analysis, we planned to divide the number of women and events by two in the group that appears twice in the analysis.

Dealing with missing data

We contacted study authors to obtain missing data in order to be able to conduct intention-to-treat analysis wherever possible. Where randomised data were not available, we have reported data from per protocol analyses as presented in the study publications. We have clearly indicated in the Effects of interventions where we have used per protocol data.

Assessment of heterogeneity

We intended to combine studies in meta-analysis where clinical and methodological heterogeneity was low; that is, studies had to be broadly similar in terms of participant characteristics, interventions, study design and outcomes in order to be pooled. Had data allowed, we would have assessed statistical heterogeneity in meta-analyses as follows, taking into account the magnitude and direction of effects as well as the P value and/or confidence interval for I²:

- 0% to 40%: heterogeneity might not be important
- 30% to 60% might represent moderate heterogeneity
- 50% to 90% might represent substantial heterogeneity
- 75% to 100% represents considerable heterogeneity
Assessment of reporting biases

Using the data extraction form, we assessed for data that could have been collected but was not reported. Where there were 10 or more studies in the same meta-analysis and where data allowed, we would have investigated reporting biases (such as publication bias) using funnel plots. If funnel plot asymmetry was suggested by a visual assessment, we would have performed exploratory analyses to investigate it.

Data synthesis

Had data allowed, we would have used a fixed-effect meta-analysis for combining data if it was reasonable to assume that the studies were estimating the same underlying treatment effect (i.e. where trials were examining the same intervention, and the trials’ populations and methods were judged sufficiently similar). If there was clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if substantial statistical heterogeneity was detected, we would have used a random-effects meta-analysis to produce an overall summary.

Subgroup analysis and investigation of heterogeneity

Had data allowed, we planned to carry out subgroup analysis according to different prolapse stages or compartments.

Sensitivity analysis

Had data allowed, we would have conducted sensitivity analyses to examine the effect of studies with high risk of bias on the results. We would have repeated the main meta-analyses without studies judged to be at high risk and compare those results to the main analyses with all studies included.

Incorporating economics evidence

Once the search outlined in the Search methods for identification of studies was performed, we developed a brief economic commentary (BEC) to summarise the availability and principal findings of the full economic evaluations that compared pessaries with alternative treatment interventions for pelvic organ prolapse in women (Shemilt 2019). This BEC encompassed full economic evaluations (i.e. cost-effectiveness analyses, cost-utility analyses and cost-benefit analyses), conducted alongside or based on one or more studies included in the main review of intervention effects, or model-based economic evaluations.

Summary of findings and assessment of the certainty of the evidence

We prepared ‘Summary of findings’ tables using the GRADEpro GDT software for the comparisons pre-stated in the Types of interventions.

We used the GRADE approach to assess the certainty of evidence related to the outcomes listed in the ‘Main outcomes for ‘Summary of findings’ tables’ in the Types of outcome measures (Schünemann 2019). We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of the body of evidence for the pre-specified outcomes. We justified all decisions to downgrade the certainty of studies using footnotes.

RESULTS

Description of studies

Results of the search

We reviewed 182 abstracts, of which 25 full-text reports (from 17 trials) were retrieved and assessed. Twelve reports of eleven trials were subsequently excluded, which are detailed in the Characteristics of excluded studies. Eleven reports of four studies were included in the review. Additionally several studies were identified within the search from their registration on clinical trial databases, and from these we identified a further two studies that, if completed, look likely to be included in future versions of this review. These studies are reported in the Characteristics of ongoing studies. The flow of literature through the assessment process for the update of this review is shown in Figure 1.
Figure 1. PRISMA study flow diagram - search for clinical effectiveness studies

182 records identified through database searching
0 additional records identified through other sources

182 records after duplicates removed

182 records screened
167 records excluded

25 full-text articles assessed for eligibility
12 reports of 11 full-text articles excluded with reasons given in Characteristics of excluded studies

11 reports of 4 trials included in the qualitative synthesis, additionally there are 2 reports of 2 ongoing studies

0 studies included in quantitative synthesis (meta-analysis)
This is the second review update. In the first version of the review, no relevant randomised controlled trials (RCTs) were identified (Adams 2004). In the first update (Bugge 2013b), we included one cross-over study (Cundiff 2007), which we have now excluded because the cross-over study design means that we cannot tell what the true effects of the pessary are.

Searches for economic evaluations to inform the development of the brief economic commentary (BEC) produced 479 unique records after removal of duplicates. We retrieved the full-text of seven articles that appeared to meet our eligibility criteria but found that three of these did not include the correct population and were therefore excluded; the remaining four reports of two economic evaluations were included in this BEC. The flow of literature through the assessment process is shown in Figure 2.
Figure 2. PRISMA study flow diagram - search for economic evaluations for the BEC

480 records identified through database searching

0 additional records identified through other sources

479 records after duplicates removed

479 records screened

472 records excluded

7 full-text articles assessed for eligibility

3 full-text articles excluded - reason: incorrect population

4 reports of 2 studies were included in the brief economic commentary (BEC)
Included studies
Four trials met the inclusion criteria. Full details are included in the Characteristics of included studies.

Design
All four included trials were RCTs. In one trial only six women were randomised before patient preference took priority and data were not reported per randomised group (Coolen 2018). The data were therefore not usable in the review.

Sample size
Sample sizes ranged from 34 (Baessler 2019) to 276 (Cheung 2016).

Setting
The included trials took place in the Netherlands (Coolen 2018; Panman 2016), Hong Kong (Cheung 2016), and Germany (Baessler 2019).

Participants
The trials included 478 women and the mean age ranged from 30.4 (Baessler 2019) to 65.6 years (Panman 2016). The trials included women with: stage I to III POP-Q symptomatic prolapse (Cheung 2016); stage II or greater symptomatic prolapse (Coolen 2018; Baessler 2019); and prolapse at or beyond the hymen (Panman 2016). One trial included women who were in the immediate postpartum period (Baessler 2019).

Length of follow-up
Follow-up in included trials ranged from six weeks (Baessler 2019) to two years (Panman 2016).

Interventions
One trial compared pessary with standard care (no interventions for six weeks postpartum) (Baessler 2019). Two trials compared pessary with another treatment: one compared pessary with pelvic floor muscle training (PFMT) (Panman 2016), while another compared pessary with surgery (Coolen 2018). One trial compared pessary plus PFMT versus PFMT alone (Cheung 2016).

Outcomes
None of the included trials reported the primary outcome of resolution of prolapse symptoms. Three trials reported the primary outcome of perceived improvement of prolapse symptoms (Baessler 2019; Cheung 2016; Panman 2016).

The secondary outcomes reported in the trials were as follows.

- Grade of prolapse (Baessler 2019; Coolen 2018; Panman 2016)
- Site-specific grading of prolapse (Baessler 2019; Coolen 2018; Panman 2016)
- Prolapse-specific quality of life (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016)
- Quality of life measured with generic quality of life or health status measures (Coolen 2018; Panman 2016)
- Cure or improvement of bladder problems (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016)
- Cure or improvement of bowel symptoms (Baessler 2019; Cheung 2016; Panman 2016)
- Cure or improvement of sexual problems (Baessler 2019; Coolen 2018; Panman 2016)
- Number of women with adverse events (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016)

None of the included studies reported data on patient-reported satisfaction with pessary treatment or psychological outcome measures.

Excluded studies
Eleven studies were excluded (see the Characteristics of excluded studies). Of these, two were excluded because it was not possible to separate the data for the women with prolapse from the data for women with urinary incontinence (Meriwether 2015; Taeger 2017). A further seven trials were excluded because they investigated pessary plus another treatment compared with pessary alone (Chou 2013; Hagen 2011b; McDermott 2012; Propst 2015; Sanker 2013; Tontivuthikul 2016; Viravaidya 2012). These studies would address the effectiveness of adding the other treatment to pessary, but it would not be evidence of the effectiveness of the pessary itself. Two studies were excluded because they did not use eligible study designs (Cundiff 2007; Danandeh 2019).

Risk of bias in included studies
See Figure 3 and Figure 4 for visual representations of the risk of bias in the included trials. Risk of bias for each included study is further detailed in the Characteristics of included studies.
Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
Figure 4. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

Allocation

Random sequence generation
Three trials had a low risk of bias for random sequence generation as they utilised remote computerised systems for randomisation (Baessler 2019; Cheung 2016; Panman 2016), Coolen 2018 had a high risk of bias as only 6/113 women in the study were randomised. For the remaining women in this study, the patients' treatment preference took priority.

Allocation concealment
All four trials had a low risk of bias for allocation concealment, as they used remote systems and in blocks of variable size, hence blinding the researchers to the possible treatment allocation (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016).

Blinding

Blinding of participants and personnel
All trials were unable to blind participants given the nature of the interventions in use (pessaries, PFMT and surgery) (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016). We therefore judged them to be at high risk of performance bias since knowledge of their assignment could influence their subjective assessment of their prolapse symptoms.

Blinding of outcome assessment
We assessed two trials as low risk of detection bias (Baessler 2019; Cheung 2016) because assessors were blinded to group allocation. One trial was judged to be at an unclear risk of bias for this domain (Coolen 2018). One trial was judged at high risk of detection bias because the outcome assessors were not blinded to group allocation (Panman 2016). In all cases where it was reported, attempts were made to blind the assessors to previous measurements.

Incomplete outcome data
One trial was assessed as high risk of attrition bias because of the substantially higher withdrawal rate in the control group (Baessler 2019). Two trials were assessed to be at a low risk of attrition bias because there was no differential attrition and the trialists conducted intention-to-treat analysis (Cheung 2016; Panman 2016). In one trial, the risk of attrition bias was unclear due to a lack of information (Coolen 2018).

Selective reporting
Three trials were assessed as having a low risk of reporting bias as all outcomes were reported across all the published material (Baessler 2019; Cheung 2016; Panman 2016). The fourth trial did not provide sufficient information to judge the risk of reporting bias and so was judged to be at unclear risk of bias (Coolen 2018).

Other potential sources of bias
There were no indications of any other kind of bias in the included trials, so all four were judged to be at low risk of bias (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016).

Effects of interventions
See: Summary of findings 1 Any pessary compared to control, waiting list or no active treatment; Summary of findings 2 Any pessary compared to pelvic floor muscle training (PFMT) for pelvic organ prolapse in women; Summary of findings 3 Pessary plus PFMT compared to pelvic floor muscle training (PFMT) alone for pelvic organ prolapse in women

Any pessary versus control, waiting list or no active treatment
One trial compared a ring pessary versus standard care (defined as no treatment for six weeks postpartum) for women who had stage II prolapse one to three days postpartum (Baessler 2019). In this trial, 13 women were randomised to pessary care and 21 to standard care.

Primary outcomes
Women's perceived resolution of prolapse symptoms
Not reported.

Women's perceived improvement in prolapse symptoms
Baessler 2019 measured improvement in prolapse symptoms using the Australian Pelvic Floor Questionnaire (Baessler 2009). We are uncertain if pessaries have any effect on women's perceived improvement in prolapse symptoms compared to standard care (mean difference (MD) -0.03, 95% confidence interval (CI) -0.61 to 0.55; 1 study; 27 women; very low-certainty evidence; Summary of findings 1; Analysis 1.1).
Secondary outcomes

Patient-reported satisfaction with pessary treatment
Not reported.

Grade of prolapse
Not reported.

Site-specific grading of prolapse

Baessler 2019 measured site-specific grading of prolapse using the POP-Q. After the pessary has been removed for a period of time, we are uncertain if it has any effect on the anatomical measurement of prolapse compared with standard care (anterior compartment: MD 0.10, 95% CI -0.73 to 0.93; 1 study, 27 women; Analysis 1.2; posterior compartment (0.10, 95% CI -0.49 to 0.69; 1 study, 27 women; Analysis 1.3).

Prolapse-specific quality of life
Not reported.

Quality of life measured with generic quality of life or health status measures
Not reported.

Psychological outcome measures
Not reported.

Cure or improvement of bladder problems

Baessler 2019 measured bladder problems using the bladder score of the Australian Pelvic Floor Questionnaire. We are uncertain if pessaries have any effect on bladder problems compared with standard care (MD -0.15, 95% CI -0.55 to 0.25; 1 study, 27 women; Analysis 1.4).

Cure or improvement of bowel problems

Baessler 2019 measured bladder problems using the bowel score of the Australian Pelvic Floor Questionnaire. We are uncertain if pessaries have any effect on bowel problems compared with standard care (MD 0.00, 95% CI -0.60 to 0.60; 1 study, 27 women; Analysis 1.5).

Cure or improvement of sexual problems

Baessler 2019 measured bladder problems using the sex score of the Australian Pelvic Floor Questionnaire. We are uncertain if pessaries have any effect on sexual problems compared with standard care (MD -0.29, 95% CI -1.67 to 1.09; 1 study; 27 women; very low-certainty evidence; Summary of findings 1; Analysis 1.6).

Number of women with adverse events (vaginal bleeding, voiding difficulty)
The adverse events of vaginal bleeding and voiding difficulty were not reported.

Any pessary versus another treatment

One trial compared a pessary with pelvic floor muscle training (PFMT) (Panman 2016). In this trial, 82 women received a pessary and 80 women received PFMT. Another trial compared a pessary with surgery (Coolen 2018). However, of the 113 women recruited to the trial only six consented to the randomisation process (two were randomised to pessary and four to surgery). The data were presented for the whole study population as a prospective cohort and therefore were not usable for this review.

Primary outcomes

Women's perceived resolution of prolapse symptoms
Not reported.

Women's perceived improvement in prolapse symptoms

Panman 2016 measured improvement in prolapse symptoms using the Pelvic Floor Disability Index (PFDI-20) (Barber 2005), and also the subscale of the PFDI measure on specific prolapse symptoms (Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6)). According to POPDI-6 scores, we are uncertain if pessaries have any effect on women’s prolapse symptoms compared with PFMT at 12 months (MD -3.60, 95% CI -8.73 to 1.53; 117 women; Analysis 2.3; low-certainty evidence Summary of findings 2), or at 24 months (MD -4.20, 95% CI -9.03 to 0.63; 141 women; Analysis 2.4). According to PFDI-20 scores at 12 months, we are uncertain if pessaries have any effect on women's prolapse symptoms compared with PFMT (MD -9.60, 95% CI -22.52 to 3.33; 137 women; Analysis 2.1). At 24 months the MD PFDI-20 was -12.10 (95% CI -25.33 to 1.13; 138 women; Analysis 2.2).

Panman 2016 reported the number of women self-reporting 'better' or 'much better' symptoms. At 24 months, we are uncertain if pessaries have any effect on women's perceived improvement in prolapse symptoms compared with PFMT because the certainty of evidence is low and the 95% CI spans possible harm and possible benefit (risk ratio (RR) 1.01, 95% CI 0.64 to 1.59; 1 study; 142 women; Analysis 2.5).

Secondary outcomes

Patient-reported satisfaction with pessary treatment
Not reported.

Grade of prolapse
Not reported.

Site-specific grading of prolapse
Not reported.

Prolapse-specific quality of life

Panman 2016 measured prolapse-specific quality of life using the PFQ-7. At 12 months’ follow-up, we are uncertain if pessaries have any effect on prolapse-specific quality of life compared to PFMT because the evidence is low certainty and the wide 95% CI is consistent with possible harm and possible benefit (MD -3.30, 95% CI -8.70 to 15.30; 1 study; 116 women; low-certainty evidence; Summary of findings 2; Analysis 2.6).

At 24 months’ follow-up it is still uncertain if pessaries have any effect on prolapse-specific quality of life compared with PFMT (MD -3.00, 95% CI -12.72 to 6.72; 133 women; Analysis 2.7).

Quality of life measured with generic quality of life or health status measures

Panman 2016 measured general quality of life using the two subscales of the SF-12 (Ware 1996) (physical health score (PCS-12); mental health score (MCS-12)). The MD between groups for the
were randomised in this trial: 137 received PFMT treatment and 139 received PFMT treatment plus a vaginal pessary.

**Primary outcomes**

**Women's perceived resolution of prolapse symptoms**

Not reported.

**Women's perceived improvement in prolapse symptoms**

At 12 months, pessary plus PFMT probably leads to more women perceiving improvement in their prolapse symptoms compared with PFMT alone (RR 2.15, 95% CI 1.58 to 2.94; 1 study; 260 women; moderate-certainty evidence; Summary of findings 3; Analysis 3.1). With pessary plus PFMT, 32.3% more women will probably feel that their symptoms have improved compared with pessary alone (16.3% more to 54.6% more).

Cheung 2016 also measured perceived improvement in prolapse symptoms using the POPDI questionnaire (and the POPDI subscale - prolapse-specific symptoms; Barber 2001). In the intention-to-treat (ITT) analysis, there was a difference at 12 months for the POPDI subscale of the PFDI for women undertaking PFMT plus pessary (median score 32.1, interquartile range (IQR) 12.5 to 78.6; 139 women) compared to those in the PFMT-only group (median score 49.4, IQR 21.4 to 95.2; 137 women; P = 0.04), which further suggests that a pessary may improve prolapse symptoms when added to PFMT.

**Secondary outcomes**

**Patient-reported satisfaction with pessary treatment**

Not reported.

**Grade of prolapse**

Not reported.

**Site-specific grade of prolapse**

Not reported.

**Prolapse-specific quality of life**

In Cheung 2016, at 12 months the women's prolapse-specific quality of life was measured using the POPQ subscale of the PFQI (higher score = worse quality of life; Barber 2001). On POPQ score, pessary plus PFMT probably improves women's prolapse-specific quality of life (median 0.3, IQR 0 to 22.2; 132 women, in comparison to the PFMT-only group (median 8.9, IQR 0 to 64.9, 128 women; P = 0.02; moderate-certainty evidence; Summary of findings 3).

**Quality of life measured with generic quality of life or health status measures**

Not reported.

**Psychological outcome measures**

Not reported.

**Cure or improvement of bladder problems**

Cheung 2016 reported the number of women with pre-existing bladder problems who reported their symptoms had improved. Compared with PFMT alone, more women in the pessary plus PFMT group perceived cure or improvement of stress urinary incontinence (SUI) (19/82 and 15/70 respectively; RR 1.08, 95% CI 0.88 to 1.32; low-certainty evidence; Summary of findings 4; Analysis 4.1). In the intention-to-treat analysis, there was a difference in cure or improvement of stress urinary incontinence at 12 months for the POPDI subscale of the PFQI (RR 1.83, 95% CI 1.21 to 2.77; 137 women; moderate-certainty evidence; Summary of findings 4; Analysis 4.2). Pessary plus PFMT probably improves women's stress urinary incontinence compared with PFMT alone (RR 1.77, 95% CI 1.25 to 2.50; 1 study; 260 women; moderate-certainty evidence; Summary of findings 4; Analysis 4.3). With pessary plus PFMT, 39.3% more women will probably feel that their symptoms have improved compared with pessary alone (14.2% more to 67.8% more).

**Secondary outcomes**

**Patient-reported satisfaction with pessary treatment**

Not reported.

**Grade of prolapse**

Not reported.

**Site-specific grade of prolapse**

Not reported.

**Prolapse-specific quality of life**

In Cheung 2016, at 12 months the women's prolapse-specific quality of life was measured using the POPQ subscale of the PFQI (higher score = worse quality of life; Barber 2001). On POPQ score, pessary plus PFMT probably improves women's prolapse-specific quality of life (median 0.3, IQR 0 to 22.2; 132 women, in comparison to the PFMT-only group (median 8.9, IQR 0 to 64.9, 128 women; P = 0.02; moderate-certainty evidence; Summary of findings 3).

**Quality of life measured with generic quality of life or health status measures**

Not reported.

**Psychological outcome measures**

Not reported.

**Cure or improvement of bladder problems**

Cheung 2016 reported the number of women with pre-existing bladder problems who reported their symptoms had improved. Compared with PFMT alone, more women in the pessary plus PFMT group perceived cure or improvement of stress urinary incontinence (SUI) (19/82 and 15/70 respectively; RR 1.08, 95% CI 0.88 to 1.32; low-certainty evidence; Summary of findings 4; Analysis 4.1). In the intention-to-treat analysis, there was a difference in cure or improvement of stress urinary incontinence at 12 months for the POPDI subscale of the PFQI (RR 1.83, 95% CI 1.21 to 2.77; 137 women; moderate-certainty evidence; Summary of findings 4; Analysis 4.2). Pessary plus PFMT probably improves women's stress urinary incontinence compared with PFMT alone (RR 1.77, 95% CI 1.25 to 2.50; 1 study; 260 women; moderate-certainty evidence; Summary of findings 4; Analysis 4.3). With pessary plus PFMT, 39.3% more women will probably feel that their symptoms have improved compared with pessary alone (14.2% more to 67.8% more).

**Secondary outcomes**

**Patient-reported satisfaction with pessary treatment**

Not reported.

**Grade of prolapse**

Not reported.

**Site-specific grade of prolapse**

Not reported.

**Prolapse-specific quality of life**

In Cheung 2016, at 12 months the women's prolapse-specific quality of life was measured using the POPQ subscale of the PFQI (higher score = worse quality of life; Barber 2001). On POPQ score, pessary plus PFMT probably improves women's prolapse-specific quality of life (median 0.3, IQR 0 to 22.2; 132 women, in comparison to the PFMT-only group (median 8.9, IQR 0 to 64.9, 128 women; P = 0.02; moderate-certainty evidence; Summary of findings 3).

**Quality of life measured with generic quality of life or health status measures**

Not reported.

**Psychological outcome measures**

Not reported.

**Cure or improvement of bladder problems**

Cheung 2016 reported the number of women with pre-existing bladder problems who reported their symptoms had improved. Compared with PFMT alone, more women in the pessary plus PFMT group perceived cure or improvement of stress urinary incontinence (SUI) (19/82 and 15/70 respectively; RR 1.08, 95% CI 0.88 to 1.32; low-certainty evidence; Summary of findings 4; Analysis 4.1). In the intention-to-treat analysis, there was a difference in cure or improvement of stress urinary incontinence at 12 months for the POPDI subscale of the PFQI (RR 1.83, 95% CI 1.21 to 2.77; 137 women; moderate-certainty evidence; Summary of findings 4; Analysis 4.2). Pessary plus PFMT probably improves women's stress urinary incontinence compared with PFMT alone (RR 1.77, 95% CI 1.25 to 2.50; 1 study; 260 women; moderate-certainty evidence; Summary of findings 4; Analysis 4.3). With pessary plus PFMT, 39.3% more women will probably feel that their symptoms have improved compared with pessary alone (14.2% more to 67.8% more).
0.60 to 1.96; 152 women; \textit{Analysis 3.2}) and cure or improvement of voiding difficulty (25/40 and 11/31 respectively; RR 1.76, 95% CI 1.03 to 3.00; 71 women; \textit{Analysis 3.4}). Fewer women in the pessary plus PFMT group perceived cure or improvement in urgency incontinence compared with PFMT alone (17/59 and 18/44 respectively; (RR 0.70, 95% CI 0.41 to 1.20; 103 women; \textit{Analysis 3.3}).

In the 12-month ITT analysis, Cheung 2016 also measured urinary symptoms using the UDI and associated quality of life using the Urinary Impact Questionnaire (UIQ).

- Median (IQR) UDI score: pessary plus PFMT 39.4 (16.9 to 74.7), 132 women; PFMT-only 37.5 (16.7 to 67.5), 128 women; \textit{P} = 0.57
- Median (IQR) UIQ score: pessary plus PFMT 13.3 (0 to 40.3), 132 women; PFMT-only 9.7 (0 to 54.8), 128 women; \textit{P} = 0.71

**Cure or improvement of bowel problems**

In the 12-month ITT analysis, Cheung 2016 measured bowel symptoms using the CRADI and associated quality of life using the CRAIQ.

- Median (IQR) CRADI score: pessary plus PFMT 32.1 (15.8 to 75.5), 132 women; PFMT-only 32.1 (14.9 to 68.0), 128 women; \textit{P} = 0.80
- Median (IQR) CRAIQ score: pessary plus PFMT 0 (0 to 5.6), 132 women; PFMT-only 0 (0 to 5.6), 128 women; \textit{P} = 0.77

**Cure or improvement of sexual problems**

Not reported.

**Number of women with adverse events (vaginal bleeding, voiding difficulty)**

Pessary plus PFMT may slightly increase the risk of abnormal vaginal bleeding compared with PFMT alone (RR 3.18, 95% CI 0.69 to 6.91; 1 study; 260 women; low-certainty evidence; \textit{Summary of findings 3; Analysis 3.5}). Pessary plus PFMT may lead to 3.7% more women having abnormal vaginal bleeding compared with PFMT alone (1% fewer to 18% more).

We are less certain if pessary plus PFMT has any effect on the risk of de novo voiding difficulty because the 95% CIs are wide and span possible harm and possible benefit (RR 1.32, 95% CI 0.54 to 3.19; 1 study; 189 women; low-certainty evidence; \textit{Analysis 3.6; Summary of findings 3}).

**One pessary versus another pessary**

No trials were identified for this comparison.

**DISCUSSION**

**Summary of main results**

Four trials involving a total of 478 women were included in this updated review. None of the included trials reported our primary outcome of women's perception of cure of prolapse symptoms. Due to the varied nature of the comparisons, it was not possible to pool data.

The evidence is very uncertain about the effect of pessaries compared with standard care on perceived improvement of prolapse symptoms, prolapse-specific quality of life, and cure or improvement of sexual problems (\textit{Summary of findings 1}). We did not find any evidence about the risk of adverse events compared with standard care (no treatment).

We are uncertain whether pessaries have any effect on women's perceived improvement in prolapse symptoms compared with pelvic floor muscle training (PFMT). We are also uncertain whether pessaries have any effect on prolapse-specific quality of life measured with the Pelvic Floor Impact Questionnaire-7 (PFIQ-7), or on cure or improvement of sexual problems measured with the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) compared with PFMT (low-certainty evidence). However, pessaries may result in a large increase in risk of adverse events compared with PFMT (low-certainty evidence). Adverse events included increased vaginal discharge, increased urinary incontinence and erosion or irritation of the vaginal walls (\textit{Summary of findings 2}).

Pessary plus PFMT probably leads to more women perceiving improvement in their prolapse symptoms and in their prolapse-specific quality of life compared with PFMT alone (moderate-certainty evidence). However, pessary plus PFMT may slightly increase the risk of abnormal vaginal bleeding compared with PFMT alone (low-certainty evidence). We are less certain if pessary plus PFMT has any effect on the risk of de novo voiding dysfunction because the 95% CIs are wide and span possible harm and possible benefit (\textit{Summary of findings 3}).

**Overall completeness and applicability of evidence**

We identified no studies comparing different types of pessaries. The studies included here are small and do not report several of our outcomes of interest. In particular, we identified no evidence regarding the effect of pessaries on women's perceived resolution of prolapse symptoms. However, the women included in the studies are largely representative of the wider population of women with pelvic organ prolapse in that they represent women with prolapse of different types, stages and across a range of ages.

Although the evidence base about vaginal pessary use for pelvic organ prolapse in women is growing, the available trials offer limited answers to the primary question regarding the effectiveness of pessaries in resolving or improving women's prolapse symptoms. In addition, we do not have adequate evidence to be certain regarding the effect of pessaries on quality of life, or their complications and adverse effects.

**Quality of the evidence**

Overall, we judged the studies to have a low risk of bias in most domains. Given that it was not possible to blind participants to their treatment allocation in any of the studies, and given that our primary outcome is subjectively reported, we judged the studies to have a high risk of performance bias. Due to imbalanced attrition and missing outcome data, we also judged some studies to have a high risk of attrition bias.

With regard to the outcomes presented in the 'Summary of findings' tables, we made decisions to downstage the certainty of evidence because of the extent of risk of bias. Additionally, we downgraded all outcomes for imprecision due to the small sample sizes in the studies.
Potential biases in the review process

We made every attempt to reduce bias in the review as far as possible, with broad inclusion criteria and a comprehensive search strategy not limited by language or publication type. We also ensured data extraction and 'Risk of bias' assessments were carried out independently by two review authors.

Brief economic commentary

In addition to the main review, we searched for economic evaluations that compared pessaries with either surgical procedures or conservative management, or both. From searches conducted in February 2020, we identified two economic evaluation studies (Hullfish 2011 and Panman 2016). We did not subject these identified economic evaluations to critical appraisal and we do not attempt to draw any firm or general conclusions regarding the relative costs or efficiency of pessaries in treating pelvic organ prolapse.

Hullfish 2011 conducted a model-based cost-utility analysis (CUA) comparing expectant management, placement of a pessary and surgical procedures (vaginal reconstructive surgery (VRS), traditional/open abdominal sacrocolpopexy, and robotic-assisted abdominal sacrocolpopexy) for post-hysterectomy pelvic organ prolapse. The study was conducted in the USA. A Markov model was developed to link potential health states and probabilistic events that follow from each treatment strategy. The model inputs include event probabilities, costs and utilities for outcomes at "a baseline case of a healthy 65 year old, post-hysterectomy female with ≥ stage III apical prolapse of the vagina, who wishes to preserve coital function". Event probabilities were mainly obtained from a review of published literature but expert knowledge was used to derive missing estimates. Due to the unavailability of health-related quality of life utility scores for pelvic organ prolapse, the authors used relative utility values that were developed based on clinical researchers' opinions. The model structure allows individuals to exist in one of seven health states during any given month over a 12-month period. These health states include pelvic organ prolapse with no complications, with presenting complications (voiding dysfunction); pessary with no complications, pessary with complication (vaginal erosion); repaired pelvic organ prolapse without late/postoperative complications (urinary tract infection); and repaired pelvic organ prolapse with major late complications (i.e. reoperation). Only direct medical costs of each treatment alternative were estimated from a number of sources for the analysis. The currency and price year are US $ and 2007 respectively. At baseline, only pessary and VRS were found to be cost-effective: pessary use yielded after 10.4 quality-adjusted months at a cost of $10,000 per patient and the VRS alternative obtained 11.4 quality-adjusted months at a cost of approximately $15,000 per patient.

In a deterministic sensitivity analysis, expectant management with VRS was efficient when baseline probability of pelvic organ prolapse complications was decreased. Pessary alternative was no longer efficient after the probability of pelvic organ prolapse complications was reduced to 0.12 and the probability of surgery following pessary use was increased to 0.17. Monte Carlo simulation results indicated that pessary use was an optimal alternative below $5600 ‘Willingness to Pay’ (WTP) per quality-adjusted life month threshold and VRS was the optimal strategy above that threshold. The authors concluded that their model demonstrated that pessary use and VRS are both cost-effective alternatives for treating hysterectomy vaginal prolapse given the context of their study.

Panman 2016 conducted both a CUA and a cost-effectiveness analysis (CEA) to compare pessary treatment with pelvic floor muscle training (PFMT) using RCT data (three follow-ups within two years) from 20 primary care practices in the Netherlands (Wiersmsa 2014). Participants included all women aged at least 55 years registered with their primary care practice. The outcome used in the CEA was distress measured by Pelvic Floor Distress Inventory-20 (PFDI-20; Barber 2005), while quality-adjusted life-years (QALYs) were measured in the CUA based on EQ-5D utility values using the UK population tariff (Dolan 1995). Only direct medical costs were included in the analysis, with a time horizon of two years. The main costs of the intervention included pessaries and pessary-related visits, costs of physical therapy, consultations with GPs and medical specialists, use of absorbent pads, medication and costs of operative procedures. Both costs and health benefits were recorded and estimated on an individual participant basis, and then the mean differences of effects and costs between the two treatment groups were estimated. The costs were valued in Euros at 2014 price level and later converted to US dollars based on the November 24 2015 exchange rate (1 Euro = 1.0657 dollars). Results of the analysis were summarised in incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) for the CEA and CUA respectively. However, the focus is on the results of the cost-effectiveness planes which, as indicated below, show the likelihood that an intervention was less costly but more effective.

The costs per person were $309 in the pessary group and $437 in the PFMT group. The mean difference was $128 (95% CI 27 to 236), with costs dependent on the primary treatment. Costs for pessaries and pessary-related visits were higher in the pessary group ($202 per person compared with 0.5 in the PFMT group), whereas costs for physical therapy were higher in the PFMT group ($324 per person for the PFMT group compared with $2 in the pessary group).

In the CUA, both treatment groups lost QALYs over the study period, with slightly less lost in the pessary group (0.024 in the pessary group and 0.065 in the PFMT group). In total, 71% of the 5000 replications in the bootstrap simulation indicated better outcomes and lower costs for the pessary group.

The authors stated that there was no difference in change in pelvic floor symptoms between pessary treatment and PFMT in women aged 55 years or older recruited by screening. Although pessary treatment led to a statistically significant greater improvement in typical prolapse symptoms compared with PFMT, the difference was small and the clinical relevance doubtful.

The authors reported that their study was the first to investigate the cost-effectiveness of pessary treatment and PFMT from such a trial and that there were no significant differences between pessary treatment and PFMT in the reduction of pelvic floor symptoms but women with apex prolapse symptoms benefited more from pessary treatment than from PFMT. Pessary treatment was preferable to PFMT in the cost-effectiveness analysis, with PFMT being more expensive but no more effective.

The interventions compared in one of the economic evaluation studies match interventions compared in Summary of findings

Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2 (Panman 2016). It would therefore be useful to compare the findings of the economic evaluation with data in Summary of findings 2.

End users of this review will need to assess the extent to which results of identified economic evaluations may be applicable (or transferable) to their own setting.

**Agreements and disagreements with other studies or reviews**

The previous version of this review (Bugge 2013b), the most recent review for the International Continence Society monograph (Dumoulin 2017), and the current review have all reached similar conclusions. All conclude that there is insufficient evidence on which to guide clinical practice surrounding prolapse management using vaginal pessaries.

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

The evidence from randomised controlled trials (RCTs) on which to base the treatment of women with pelvic organ prolapse using vaginal pessaries remains very limited. The research base is growing but more trials are needed in order for data to be pooled in a way that will allow for greater certainty in recommendations for treatment. Clinical staff may wish to read this review alongside the surgical Cochrane Reviews (Baessler 2018; Maher 2016a; Maher 2016b; Maher 2016c; Mowat 2018) and the Cochrane Review of conservative and lifestyle measures (Hagen 2011a).

In the postpartum period, one small trial compared pessary versus standard care (no treatment for six weeks), and across the available comparisons the certainty of evidence was very low, making recommendations for practice in the postpartum period difficult. Panman 2016 compared pessary versus pelvic floor muscle training (PFMT), and it was uncertain if pessary had an effect on women’s perceived improvement in prolapse symptoms in comparison to PFMT. Both PFMT and pessary are active treatments and, as such, it is not known if improvements were greater than if no treatment had been given. Cheung 2016 added a pessary to PFMT and probably led to more women perceiving an improvement in prolapse symptoms. It may be that practitioners consider the added benefit of a pessary for women with prolapse who are receiving PFMT.

There was some evidence of an increase in adverse events with pessary use. However, the clinical significance of these adverse events is unknown but may be argued to be low. Specifically, increased vaginal bleeding and discharge may be adverse events a woman is willing to accept if she experiences a decrease in prolapse symptoms. De novo stress urinary incontinence (SUI) may be a more problematic adverse event for women, but the evidence surrounding the effects of pessary on de novo SUI are not certain. While some evidence is suggestive of an increase in adverse events for women who use a pessary for prolapse, the extent to which these events are bothersome for women requires further investigation before recommendations can be made for practice.

**Implications for research**

Adequately-powered trials measuring clinically-important outcomes are urgently needed to guide international practice. The comparison between pessary and no active treatment is perhaps difficult as there is observational evidence suggesting benefit of pessary and other conservative treatments, making a no active treatment group possibly unacceptable to women or policy makers (Hagen 2011a; Lamers 2011).

Across the other comparisons more research is needed, specifically: pessary versus another active treatment; pessary as an adjunct to other treatments; and comparison between pessary types. It is important that future trials measure women’s perceived resolution of prolapse symptoms. Qualitative research about the bothersomeness of adverse events of pessary use would also support the understanding of adverse event reporting in the trials. As the evidence base evolves, it will also be helpful to explore the effectiveness of pessary for different stages and types of prolapse.

This review identified only two relevant economic evaluations, which highlights both the lack of economic evidence and the need to conduct more economic evaluations on prolapse interventions that includes pessaries.

**ACKNOWLEDGEMENTS**

We are grateful to Chantale Dumoulin and Durhane Wong-Rieger for their valuable comments on drafts of the review, along with a health economist who provided feedback on the brief economic commentary. We thank Sheila Wallace for assistance with searches for this review and Muhammad Imran Omar, Lindsey Elstub and Eugenie Johnson for advice on undertaking and reporting the review.

We acknowledge the contributions of Suzanne Hagen, who was an author on the original review, and Fiona Reid, who was an author on the first revision of the review.
REFERENCES

References to studies included in this review

Panman 2019 (published and unpublished data)


References to studies excluded from this review

Cheung 2016 (published data only)

Cheung RY, Chan SS, Lee LL, Lee JH. 12 months outcome of women with symptomatic pelvic organ prolapse: vaginal ring pessary versus conservative treatment. In: 45th Annual Meeting of the International Continence Society (ICS), 2015 Oct 6-9, Montreal, Canada. 2015. [Abstract number 397] [CUHK_CCT00302] [sr-incont78490]

Cheung RY, Chan SS, Lee LL, Lee JH. Changes in urinary symptom in women treated with vaginal pessary with symptomatic pelvic organ prolapse - a randomized controlled trial. In: 45th Annual Meeting of the International Continence Society (ICS), 2015 Oct 6-9, Montreal, Canada. 2015. [Abstract number 377] [CUHK_CCT00302] [sr-incont68811]

Cheung RY, Lee JH, Lee LL, Chung TK, Chan SS. Vaginal pessary in women with symptomatic pelvic organ prolapse: a randomized controlled trial. Obstetrics and Gynecology 2016;128(1):73-80. [DOI: 10.1097/AOG.0000000000001489] [CUHK_CCT00302] [ChiCTR-TRC-11001796] [sr-incont72969]


Coolen 2018 (published and unpublished data)


Coolen AL. Primary treatment of vaginal prolapse: pessary use versus prolapse surgery - ROK. trialregister.nl/trial/2719 (first received 17 April 2011). [NL2719 (NTR2856)] [Source ID: 0826] [TrialID: ROK] [sr-incont65492]


Panman 2016 (published data only)


References to studies included in this review

Baessler 2019 (published and unpublished data)


Cheung 2016 (published data only)

Cheung RY, Chan SS, Lee LL, Lee JH. 12 months outcome of women with symptomatic pelvic organ prolapse: vaginal ring pessary versus conservative treatment. In: 45th Annual Meeting of the International Continence Society (ICS), 2015 Oct 6-9, Montreal, Canada. 2015. [Abstract number 397] [CUHK_CCT00302] [sr-incont68811]

Cheung RY, Chan SS, Lee LL, Lee JH. Changes in urinary symptom in women treated with vaginal pessary with symptomatic pelvic organ prolapse - a randomized controlled trial. In: 45th Annual Meeting of the International Continence Society (ICS), 2015 Oct 6-9, Montreal, Canada. 2015. [Abstract number 377] [CUHK_CCT00302] [sr-incont68810]

* Cheung RY, Lee JH, Lee LL, Chung TK, Chan SS. Vaginal pessary in women with symptomatic pelvic organ prolapse: a randomized controlled trial. Obstetrics and Gynecology 2016;128(1):73-80. [DOI: 10.1097/AOG.0000000000001489] [CUHK_CCT00302] [ChiCTR-TRC-11001796] [sr-incont72969]


Coolen 2018 (published and unpublished data)


Coolen AL. Primary treatment of vaginal prolapse: pessary use versus prolapse surgery - ROK. trialregister.nl/trial/2719 (first received 17 April 2011). [NL2719 (NTR2856)] [Source ID: 0826] [TrialID: ROK] [sr-incont65492]


Panman 2016 (published data only)

References to ongoing studies

Meriwether 2015 (published data only)

Propst 2015 (published data only)

Sanker 2013 (published data only)
Sanker V, Suvarna S. A clinical trial to study the effects of traditional treatments in patients with pelvic organ prolapse [A controlled prospective open labelled study to evaluate the traditional management of pelvic organ prolapse]. ctrl.nic.in/Clinicaltrials/psmaindet2.php?trialid=6069 (first received 17 April 2013). [CTRI/2013/04/003583] [sr-incont5481]

Taeger 2017 (published data only)

Tontivuthikul 2016 (published data only)

Viravaidya 2012 (published data only)

References to ongoing studies

Cornish 2018 (published data only)

van de Waarsenburg 2014 (published data only)
Van de Waarsenburg MK, van der Vaart CH. Pessary or prolapse surgery for symptomatic pelvic organ prolapse. trialregister.nl/trial/4756 (first received 18 November 2014). [NL4756 (NTR4883)] [sr-incont65472]

Additional references

Abdel-Fattah 2011

Baessler 2009

Baessler 2018

Barber 2001

Barber 2005

Basu 2011

Brazell 2014

Bugge 2013a

Bugge 2020 [pers comm]

Bump 1996
**Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)**

**Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**

---

**Bump 1998**


---

**Clemons 2004a**


---

**Clemons 2004b**


---

**Clemons 2004c**

Clemons JL, Aguilar VC, Sokol ER, Jackson ND, Myers DL. Patient characteristics that are associated with continued pessary use versus surgery after 1 year. *American Journal of Obstetrics and Gynecology* 2004;191(1):159-64.

---

**CRD 2015**


---

**Cundiff 2000**


---

**Dietz 2008**


---

**Dolan 1995**


---

**Dumoulin 2017**


---

**Dwyer 2019**


---

**EndNote 2018 [Computer program]**


---

**Enemchukwu 2019**


---

**Gorti 2009**


---

**GRADEpro GDT [Computer program]**

McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 5 May 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.

---

**Gyhagen 2015**


---

**Hagen 2009**


---

**Hagen 2011a**


---

**Hanson 2006**


---

**Hendrix 2002**


---

**Higgins 2011**


---

**Higgins 2019**

Pessary (mechanical devices) for managing pelvic organ prolapse in women (Review)

Hullfish 2011

Jelovsek 2006

Jelovsek 2018

Kapoor 2009

Lamers 2011

Lone 2011

Lough 2018

Lowder 2011

MacLennan 2000

Maher 2016a

Maher 2016b

Maher 2016c

Manchana 2012

Mowat 2018

NICE 2019

Oliver 2011

Pakbaz 2010

Poma 2000

Pott-Grinstein 2001

Primary Care Women’s Health Forum 2019

Schünemann 2019

**Shemilt 2019**

**Subak 2001**

**Ware 1993**

**Ware 1996**

**Wiegersma 2014**

**Wu 2009**

**Wu 2011**
Wu JM, Kawasaki A, Hundley AF, Dieter AA, Myers ER, Sung VW. Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. *American Journal of Obstetrics and Gynecology* 2011;205(3):230.e1-5.

**Zigmond 1983**

**References to other published versions of this review**

**Adams 2002**

**Adams 2004**

**Bugge 2013b**

* Indicates the major publication for the study

**CHARACTERISTICS OF STUDIES**

**Characteristics of included studies** [ordered by study ID]

**Baessler 2019**

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Design: two-arm parallel RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td><strong>Country: Germany</strong></td>
</tr>
<tr>
<td><strong>Number of participants: 34</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Mean age:</strong> pessary group 32 (SD 5.6); standard care 30.4 (SD 6.6)</td>
<td></td>
</tr>
<tr>
<td><strong>Prolapse staging:</strong> stage II</td>
<td></td>
</tr>
<tr>
<td><strong>Prolapse compartment:</strong> anterior and posterior</td>
<td></td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> women 18 and over, first vaginal delivery, stage 2 POP (examination or perineal ultrasond in standing position)</td>
<td></td>
</tr>
</tbody>
</table>
### Baessler 2019 (Continued)

#### Exclusion criteria:
severe diseases of mother/child, previous pelvic surgery, neurological diseases, severe perineal post partum pain, high vaginal tears

#### Interventions

| Group I (n = 13): vaginal ring pessary |
| Group II (n = 21): standard care (no interventions for six weeks postpartum) |

#### Outcomes

| Primary outcome: prolapse symptoms measured using the Australian Pelvic Floor Questionnaire (German version with validated postpartum module) at 12 months |
| Secondary outcomes: POP-Q, pelvic ultrasound for bladder neck and puborectalis at rest and on straining in standing |

#### Notes

| Funding source: not reported |
| Declarations of interest: J Stupin discloses Arabin GmbH: Consultant, all other authors state they have noting to disclose. |
| Trial stopped early due to poor recruitment and 'occasional pessary problems which were solved with pessary removal' |

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>PC-generated randomisation list put into opaque envelopes. Preference was permitted but data are available for randomised group only</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Opaque envelopes opened after consent and examination for levator avulsion</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Not possible to blind participant or caregiver.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Assessors blinded to group allocation.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Some differential loss to follow-up (1/13 in pessary group, 6/21 in standard care group).</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Data provided on measured outcomes.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None</td>
</tr>
</tbody>
</table>

#### Cheung 2016

#### Study characteristics

| Methods | Design: parallel group RCT |
| Dates study conducted: | December 2011 to November 2014 |
Participants

Setting: Hong Kong, single centre

Number of participants: 276 women with pelvic organ prolapse stages I to III (POP-Q)

Mean age: PFMT group 62.7 (SD 10.2); pessary group 62.5 (SD 9.1)

Prolapse staging:

PFMT group: stage I n = 14 (10%); stage II n = 92 (67%); stage III n = 31 (23%)

Pessary group: stage I n = 11 (8%), stage II n = 96 (69%) stage III n = 32 (23%)

Prolapse compartment:

PFMT group: anterior n = 91 (61.4%); apical n = 38 (27.7%); posterior n = 8 (5.8%)

Pessary group: anterior n = 90 (64.7%); apical n = 45 (32.4%); posterior n = 4 (2.9%)

Inclusion criteria: symptomatic pelvic organ prolapse stage I to III (POP-Q), no previous treatment

Exclusion criteria: complications that arise from prolapse, confirmed urinary retention, vaginal erosion or ulcer that required active treatment, impaired mobility, cognitive impairment, language barrier that prevented questionnaire completion

Interventions

Group I (n = 137): PFMT treatment alone

Group II (n = 139): vaginal ring pessary plus conservative treatment

Outcomes

Primary outcome: PFDI and PFIQ plus subscales

Secondary outcome: discomfort from prolapse symptoms (VAS score), desired treatment, complications

Notes

Funding source: not reported

Declarations of interest: quote: "The authors did not report any potential conflicts of interest"

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Women randomised using random computer-generated numbers and allocated in serially numbered envelopes.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Allocated by random number series</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Participants not blinded to treatment. Investigator who took history and recorded POP-Q blinded to group allocation.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Primary outcome self-completion. Investigator who took history and recorded POP-Q blinded to group allocation.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>135/139 in pessary group and 130/137 in PFMT alone group completed measures at 12 months.</td>
</tr>
</tbody>
</table>
Cheung 2016 (Continued)

Selective reporting (reporting bias)  Low risk  Not all outcomes listed in Trial registry and paper presented but main outcomes are presented and they have reported outcomes of interest to this review

Other bias  Low risk  None.

Coolen 2018

Study characteristics

Methods
Design: parallel group RCT
Dates study conducted: June 2009 and July 2014

Participants
Setting: single centre
Country: the Netherlands
Number of participants: 113 women
Mean age: not reported for randomised group (for cohort 63 years for pessary group; 58 surgical group - pessary group significantly older)
Prolapse staging: not reported for randomised group
Inclusion criteria: symptomatic prolapse POP-Q stage II or greater, with bothersome urogynaecological symptoms who wanted to undergo treatment
Exclusion criteria: previous prolapse or incontinence surgery, previous pessary treatment, patients in whom surgery was contraindicated, isolated rectocele without prolapse in any other compartment

Interventions
Group I (n = 74): pessary: Portex, Falk
Group II (n = 39): prolapse surgery: vaginal hysterectomy; anterior colporrhaphy; posterior colporrhaphy; a combination of these surgical treatments; a combination of these surgical treatments including MESH material.
Two randomised to pessary and four to surgery. All other women chose treatment by preference (72 pessary, 35 surgery).

Outcomes
Primary outcome: disease-specific quality of life - prolapse domain of Urinary Distress Inventory (UDI)
Secondary outcomes: general quality of life (werkgroepbekkenbodem, EURQOL, SF36); successful continuous pessary treatment; anatomical outcome (POP-Q).

Notes
Funding source: not reported
Declarations of interest: not reported
Data on the six randomised women were not available in the published study reports. We were in communication with the trialists regarding obtaining these data but the global pandemic of 2020 meant we had to pause this process - we will re-establish contact with the trialists for the next review update (Bugge 2020 [pers comm]).

Risk of bias

Bias
Authors' judgement  Support for judgement
### Coolen 2018 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>High risk</td>
<td>Only six women randomised, patient preference took priority.</td>
</tr>
<tr>
<td>Allocation concealment</td>
<td>Low risk</td>
<td>Allocation in sealed opaque envelopes.</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>High risk</td>
<td>Blinding not possible.</td>
</tr>
<tr>
<td>Blinding of outcome assessment</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Unclear risk</td>
<td>Not known for randomised group</td>
</tr>
<tr>
<td>Selective reporting</td>
<td>Unclear risk</td>
<td>Not known for randomised group</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None</td>
</tr>
</tbody>
</table>

### Panman 2016

#### Study characteristics

**Methods**

- **Design:** parallel group RCT
- **Dates study conducted:** October 2009 to December 2012

**Participants**

- **Setting:** multicentre (women recruited from 20 general practices)
- **Country:** the Netherlands
- **Number of participants:** 162 women with prolapse at or beyond hymen (POP-Q measured)
- **Mean age:** PFMT group 65.6 (SD 6.4); pessary group 64.9 (SD 7.4)

**Prolapse staging:**

- PFMT group: stage II 77.5% (n = 62); stage III 22.5% (n = 18).
- Pessary group: stage II 70.7% (n = 58); stage III 29.3% (n = 24).

**Prolapse compartment:**

- PFMT group: anterior 31.3% (n = 25), posterior 3.8% (n = 3), apical 0% (n = 0), anterior and posterior 32.5% (n = 26), anterior and apical 10% (n = 8), posterior and apical 2.5% (n = 2), anterior and posterior and apical 20% (n = 16)
- Pessary group: anterior 24.7% (n = 20), posterior 0% (n = 0), apical 0% (n = 0), anterior and posterior 28.4% (n = 23), anterior and apical 23.5% (n = 19), posterior and apical 0% (n = 0), anterior and posterior and apical 23.5% (n = 19)

**Inclusion criteria:** women aged 55 years and older, GP registered, self-identified prolapse symptoms (using screening tool), prolapse at or beyond hymen using POP-Q
Exclusion criteria: current prolapse treatment (or within the last year for PFMT, pessary or surgery), current treatment for gynaecological or urological disorder, current gynaecological or urological malignancy, severe/terminal illness, inability to visit GP office, cognitive impairment, inability to understand complete Dutch questionnaires, stage IV prolapse

Interventions

Group I (n = 80): PFMT. Delivered by a registered pelvic physiotherapist registered with Dutch Pelvic Physio Association. Started with explanation of pelvic floor function, if unable to contract taught this first, women did exercises during physiotherapy contact and at home three to five times a week and two to three times a day. All participants started with same exercise regimen and then individual adaptation in line with normal practice (included being able to use electrical stimulation). All taught the knack. Attention paid to lifestyle and toileting habits. At three-month follow-up all PFMT group received a leaflet with information and advice on lifestyle and continuing PFMT.

Group II (n = 82): pessary. Fitted by quote: “trained research physician” (n = 4). Two-week trial of pessary with refit at two weeks if necessary (maximum of three refits); first ring, then ring with support and then Shaatz or Gellhorn (all silicone). Follow-up started as soon as successful fit achieved. Additional visits (to GP or research physician) to clean pessary and monitor side effects every three months. Topical oestrogen used for vaginal decubitus.

Outcomes

Primary outcome: distress caused by pelvic floor symptoms measured by PFDI-20

Secondary outcomes: three subscales of PFDI-20, condition-specific and general quality of life, sexual function, pelvic floor muscle function, POP-Q, post void residual volume, patients’ perception of improvement, costs

Notes

Funding source: quote: “funded by the Netherlands Organisation for Health Research and Development (ZonMw), project number 4201.1001”; “The funding organization had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.”

Declarations of interest: quote: “The authors declare no conflict of interest.”

There is both the main paper that presented an intention-to-treat and per protocol analysis. The full trial protocol is published (Panman 2016). Data for intention-to-treat analysis available in main paper, plus one conference abstract about the completed case analysis at three months (those with unsuccessful pessary fitting excluded).

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomised in a 1:1 ratio using external (remotely accessed) computerised system in variable block size</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Enrolling physician blind to block size and allocation sequence. Allocation using remotely accessed computer system.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Patients and treating health professionals not blinded to treatment allocation.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Research physicians were not blinded to allocation and outcomes may have been influenced by their knowledge of allocation.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>70/80 in PFMT group and 74/82 in pessary group at 24 months</td>
</tr>
</tbody>
</table>
Panman 2016 (Continued)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Data are presented across outcomes</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None</td>
</tr>
</tbody>
</table>

GP: general practitioner  
PFDI-20: Pelvic Floor Disability Index  
PFIQ: Pelvic Floor Impact Questionnaire  
PFMT: pelvic floor muscle training  
POP: pelvic organ prolapse  
POP-Q: Pelvic Organ Prolapse Quantification  
RCT: randomised controlled trial  
SD: standard deviation  
SF36: Short Form 36  
UDI: Urinary Distress Index  
VAS: visual analogue scale

Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chou 2013</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>Cundiff 2007</td>
<td>Ineligible study design (cross-over RCT)</td>
</tr>
<tr>
<td>Danandeh 2019</td>
<td>Ineligible study design (not RCT)</td>
</tr>
<tr>
<td>Hagen 2011b</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>McDermott 2012</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>Meriwether 2015</td>
<td>Not possible to separate data for women who had prolapse or prolapse plus incontinence from women who had incontinence alone</td>
</tr>
<tr>
<td>Propst 2015</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>Sanker 2013</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>Taege 2017</td>
<td>Not possible to separate data for women who had prolapse or prolapse plus incontinence from women who had incontinence alone</td>
</tr>
<tr>
<td>Tontivuthikul 2016</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>Viravaidya 2012</td>
<td>Ineligible intervention</td>
</tr>
</tbody>
</table>

RCT: randomised controlled trial

Characteristics of ongoing studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study name</th>
<th>Study name</th>
</tr>
</thead>
</table>

| Methods | Design: parallel RCT |
Participants

**Inclusion criteria**: women who are at least 18 years of age with symptomatic pelvic organ prolapse, able to speak and read English, no previous use of a vaginal pessary for prolapse, at least stage II prolapse for any single compartment or multi-compartment prolapse, willing to use a ring pessary, willing and able to complete questionnaires and follow-up visits.

**Exclusion criteria**: refusal to participate, unable to speak or read English, women under 18 years of age, previous vaginal pessary use, prior prolapse surgery, contraindications to topical oestrogen therapy, unwilling to use a vaginal pessary, unable and unwilling to complete questionnaires and attend follow-up visits.

Interventions

**Group I**: a silicon irregular hexagonal pessary

**Group II**: PVC ring pessary

Outcomes

**Primary outcome**: treatment success (defined as retention of the pessary at 6 months and 12 months post randomisation)

**Secondary outcomes**: self-reported ability to self-care at 6 and 12 months; satisfaction with pessary treatment based on PFDI-20, PISQ 12 and EQSD at 6 and 12 months; adverse events at 6 and 12 months.

Starting date

2018

Contact information

chin.yong@thewomens.org.au

Notes

This trial is ongoing.

**van de Waarsenburg 2014**

Study name

Pessary or prolapse surgery for symptomatic pelvic organ prolapse (PEOPLE)

Methods

Multicentre pragmatic cohort study with an embedded randomised controlled non-inferiority trial comparing pessary therapy versus surgery including an economic evaluation

Participants

The aim is to recruit 436 women.

**Inclusion criteria**: women with prolapse stage 2 or more, women with moderate to severe prolapse symptoms (score of > 33 on PFDI-20), women with successful pessary fitting, written informed consent

**Exclusion criteria**: prior urogynaecological (prolapse or incontinence) surgery, probability of future childbearing, insufficient knowledge of Dutch language, comorbidity causing increased surgical risks (at surgeon discretion), major psychiatric illness, prior pessary use

Interventions

**Group I**: pessary

**Group II**: vaginal prolapse surgery

Outcomes

**Primary outcome**: global impression of improvement of prolapse symptoms at 24 months (PGI-I)

**Secondary outcome**: change in symptom bother and disease-specific quality of life at 12 and 24 months, changes in sexual function at 12 and 24 months, changes in general quality of life at 3, 6, 12 and 24 months, adverse events/complications, development of prediction model to identify factors for failing of pessary and surgery, cost-effectiveness analysis
van de Waarsenburg 2014 (Continued)

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Women’s perceived improvement in prolapse symptoms: POP score of Australian Pelvic Floor Questionnaire at 12 months (range 0-10, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.2 Site-specific grading of prolapse - anterior - (measured with POP-Q) at 12 months</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.3 Site-specific grading of prolapse - posterior - (measured with POP-Q) at 12 months</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.4 Cure or improvement of bladder problems at 12 months (measured with bladder score of Australian Pelvic Floor Questionnaire, range 0-10, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.5 Cure or improvement of bowel problems at 12 months (measured with bowel score of Australian Pelvic Floor Questionnaire, range 0-10, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.6 Cure or improvement of sexual problems at 12 months (measured with sex score of Australian Pelvic Floor Questionnaire, range 0-10, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcomes 1: Women’s perceived improvement in prolapse symptoms: POP score of Australian Pelvic Floor Questionnaire at 12 months (range 0-10, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Mean</th>
<th>SD</th>
<th>Total</th>
<th>Control Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baessler 2019</td>
<td>0.28</td>
<td>0.78</td>
<td>12</td>
<td>0.31</td>
<td>0.75</td>
<td>15</td>
<td>-0.03 [-0.61 , 0.55]</td>
<td></td>
</tr>
</tbody>
</table>

![Favours pessary/Favours control graph](image1.png)

### Analysis 1.2. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 2: Site-specific grading of prolapse - anterior - (measured with POP-Q) at 12 months

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Mean</th>
<th>SD</th>
<th>Total</th>
<th>Control Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baessler 2019</td>
<td>-1.2</td>
<td>1.1</td>
<td>12</td>
<td>-1.3</td>
<td>1.1</td>
<td>15</td>
<td>0.10 [-0.73 , 0.93]</td>
<td></td>
</tr>
</tbody>
</table>

![Favours pessary/Favours control graph](image2.png)

### Analysis 1.3. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 3: Site-specific grading of prolapse - posterior - (measured with POP-Q) at 12 months

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Mean</th>
<th>SD</th>
<th>Total</th>
<th>Control Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baessler 2019</td>
<td>-2.1</td>
<td>0.9</td>
<td>12</td>
<td>-2.2</td>
<td>0.6</td>
<td>15</td>
<td>0.10 [-0.49 , 0.69]</td>
<td></td>
</tr>
</tbody>
</table>

![Favours pessary/Favours control graph](image3.png)

### Analysis 1.4. Comparison 1: Any pessary versus control, waiting list or no active treatment, Outcome 4: Cure or improvement of bladder problems at 12 months (measured with bladder score of Australian Pelvic Floor Questionnaire, range 0-10, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Mean</th>
<th>SD</th>
<th>Total</th>
<th>Control Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baessler 2019</td>
<td>0.47</td>
<td>0.49</td>
<td>12</td>
<td>0.62</td>
<td>0.58</td>
<td>15</td>
<td>-0.15 [-0.55 , 0.25]</td>
<td></td>
</tr>
</tbody>
</table>

![Favours pessary/Favours control graph](image4.png)
Comparison 2. Any pessary versus PFMT

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Women’s perceived improvement of prolapse symptoms at 12 months (measured with PFDI-20; range: 0-300, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.2 Women’s perceived improvement of prolapse symptoms at 24 months (measured with PFDI-20; range: 0-300, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.3 Women’s perceived improvement of prolapse symptoms at 12 months (measured with POPDI-6; range: 0-100, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.4 Women’s perceived improvement of prolapse symptoms at 24 months (POPDI-6; range: 0-100, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.5 Women’s perceived improvement of prolapse symptoms at 24 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.6 Prolapse-specific quality of life at 12 months (measured with PFIQ-7; range: 0-300, higher score = worse QoL)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.7 Prolapse-specific quality of life at 24 months (measured with PFIQ-7; range: 0-300, higher score = worse QoL)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>Outcome or subgroup title</td>
<td>No. of studies</td>
<td>No. of participants</td>
<td>Statistical method</td>
<td>Effect size</td>
</tr>
<tr>
<td>---------------------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>--------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>2.8 Quality of life at 12 months (measured with PCS-12, range: 0-100, higher score = better health status)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.9 Quality of life at 24 months (measures with PCS-12, range: 0-100, higher score = better health status)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.10 Quality of life at 12 months (measured with MCS-12, range: 0-100, higher score = better health status)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.11 Quality of life at 24 months (measured with MCS-12, range: 0-100, higher score = better health status)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.12 Cure or improvement of bladder problems at 12 months (measured with UDI-6, range: 0-100, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.13 Cure or improvement of bladder problems at 24 month (measured with UDI-6, range: 0-100, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.14 Cure or improvement of bowel problems at 12 months (measured with CRADi-8, range: 0-100, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.15 Cure or improvement of bowel problems at 24 months (measured with CRADi-8, range: 0-100, higher score = worse symptoms)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.16 Cure or improvement of sexual problems at 12 months (measured with PISQ-12, range: 0-48, higher score = better sexual functioning)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.17 Cure or improvement of sexual problems at 24 months (measured with PISQ-12, range: 0-48, higher score = better sexual functioning)</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.18 Number of women with adverse events</td>
<td>1</td>
<td>97</td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>75.25 [4.70, 1205.45]</td>
</tr>
</tbody>
</table>

### Analysis 2.1. Comparison 2: Any pessary versus PFMT, Outcome 1: Women's perceived improvement of prolapse symptoms at 12 months (measured with PFDI-20; range: 0-300, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Pessary</th>
<th>SD Pessary</th>
<th>Total Pessary</th>
<th>Mean PFMT</th>
<th>SD PFMT</th>
<th>Total PFMT</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>50.6</td>
<td>35.9</td>
<td>71</td>
<td>60.2</td>
<td>40.9</td>
<td>66</td>
<td>-9.60 [-22.53 , 3.33]</td>
</tr>
</tbody>
</table>
## Analysis 2.2. Comparison 2: Any pessary versus PFMT, Outcome 2: Women’s perceived improvement of prolapse symptoms at 24 months (measured with PFDI-20; range: 0-300, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Mean</th>
<th>SD</th>
<th>Total</th>
<th>PFMT Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>50.5</td>
<td>34.7</td>
<td>71</td>
<td>62.6</td>
<td>43.8</td>
<td>67</td>
<td>-12.10 [-25.33 , 1.13]</td>
<td></td>
</tr>
</tbody>
</table>

## Analysis 2.3. Comparison 2: Any pessary versus PFMT, Outcome 3: Women’s perceived improvement of prolapse symptoms at 12 months (measured with POPDI-6; range: 0-100, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Mean</th>
<th>SD</th>
<th>Total</th>
<th>PFMT Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>12.8</td>
<td>12.8</td>
<td>48</td>
<td>16.4</td>
<td>15.4</td>
<td>69</td>
<td>-3.60 [-8.73 , 1.53]</td>
<td></td>
</tr>
</tbody>
</table>

## Analysis 2.4. Comparison 2: Any pessary versus PFMT, Outcome 4: Women’s perceived improvement of prolapse symptoms at 24 months (POPDI-6; range: 0-100, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Mean</th>
<th>SD</th>
<th>Total</th>
<th>PFMT Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>12.9</td>
<td>13.1</td>
<td>73</td>
<td>17.1</td>
<td>15.9</td>
<td>68</td>
<td>-4.20 [-9.03 , 0.63]</td>
<td></td>
</tr>
</tbody>
</table>

## Analysis 2.5. Comparison 2: Any pessary versus PFMT, Outcome 5: Women’s perceived improvement of prolapse symptoms at 24 months

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary Events</th>
<th>Total</th>
<th>PFMT Events</th>
<th>Total</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
<th>Risk Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>25</td>
<td>72</td>
<td>24</td>
<td>70</td>
<td>1.01 [0.64 , 1.59]</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 2.6. Comparison 2: Any pessary versus PFMT, Outcome 6: Prolapse-specific quality of life at 12 months (measured with PFIQ-7, range: 0-300, higher score = worse QoL)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>3.30 [-8.70, 15.30]</td>
</tr>
</tbody>
</table>

### Analysis 2.7. Comparison 2: Any pessary versus PFMT, Outcome 7: Prolapse-specific quality of life at 24 months (measured with PFIQ-7, range: 0-300, higher score = worse QoL)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>-3.00 [-12.72, 6.72]</td>
</tr>
</tbody>
</table>

### Analysis 2.8. Comparison 2: Any pessary versus PFMT, Outcome 8: Quality of life at 12 months (measured with PCS-12, range: 0-100, higher score = better health status)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>1.20 [-2.45, 4.85]</td>
</tr>
</tbody>
</table>

### Analysis 2.9. Comparison 2: Any pessary versus PFMT, Outcome 9: Quality of life at 24 months (measured with PCS-12, range: 0-100, higher score = better health status)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>2.30 [-1.01, 5.61]</td>
</tr>
</tbody>
</table>
### Analysis 2.10. Comparison 2: Any pessary versus PFMT, Outcome 10: Quality of life at 12 months (measured with MCS-12, range: 0-100, higher score = better health status)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>PFMT</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td></td>
<td>51.6</td>
<td>10.3</td>
<td>43</td>
<td>53.5</td>
<td>8.3</td>
<td>65</td>
<td>-1.90 [-5.58, 1.78]</td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 2.11. Comparison 2: Any pessary versus PFMT, Outcome 11: Quality of life at 24 months (measured with MCS-12, range: 0-100, higher score = better health status)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>PFMT</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td></td>
<td>52.2</td>
<td>9.4</td>
<td>70</td>
<td>53.9</td>
<td>7.9</td>
<td>60</td>
<td>-1.70 [-4.67, 1.27]</td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 2.12. Comparison 2: Any pessary versus PFMT, Outcome 12: Cure or improvement of bladder problems at 12 months (measured with UDI-6, range: 0-100, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>PFMT</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td></td>
<td>22.3</td>
<td>17.9</td>
<td>47</td>
<td>25</td>
<td>18.5</td>
<td>68</td>
<td>-2.70 [-9.45, 4.05]</td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 2.13. Comparison 2: Any pessary versus PFMT, Outcome 13: Cure or improvement of bladder problems at 24 month (measured with UDI-6, range: 0-100, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>PFMT</th>
<th>Mean</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td></td>
<td>24.4</td>
<td>16</td>
<td>72</td>
<td>26.6</td>
<td>20.6</td>
<td>68</td>
<td>-2.20 [-8.33, 3.93]</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 2.14. Comparison 2: Any pessary versus PFMT, Outcome 14: Cure or improvement of bowel problems at 12 months (measured with CRADI-8, range: 0-100, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Pessary</th>
<th>SD</th>
<th>Total</th>
<th>Mean PFMT</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>14.2</td>
<td>12.3</td>
<td>48</td>
<td>17.7</td>
<td>15.5</td>
<td>66</td>
<td>-3.50 [-8.61 , 1.61]</td>
</tr>
</tbody>
</table>

Mean Difference IV, Fixed, 95% CI: -3.50 [-8.61 , 1.61]

Favours PFMT

Favours pessary

### Analysis 2.15. Comparison 2: Any pessary versus PFMT, Outcome 15: Cure or improvement of bowel problems at 24 months (measured with CRADI-8, range: 0-100, higher score = worse symptoms)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Pessary</th>
<th>SD</th>
<th>Total</th>
<th>Mean PFMT</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>13.6</td>
<td>13.4</td>
<td>72</td>
<td>18.1</td>
<td>16</td>
<td>69</td>
<td>-4.50 [-9.38 , 0.38]</td>
</tr>
</tbody>
</table>

Mean Difference IV, Fixed, 95% CI: -4.50 [-9.38 , 0.38]

Favours PFMT

Favours pessary

### Analysis 2.16. Comparison 2: Any pessary versus PFMT, Outcome 16: Cure or improvement of sexual problems at 12 months (measured with PISQ-12, range: 0-48, higher score = better sexual functioning)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Pessary</th>
<th>SD</th>
<th>Total</th>
<th>Mean PFMT</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>35.3</td>
<td>5.9</td>
<td>24</td>
<td>37.6</td>
<td>4.2</td>
<td>24</td>
<td>-2.30 [-5.20 , 0.60]</td>
</tr>
</tbody>
</table>

Mean Difference IV, Fixed, 95% CI: -2.30 [-5.20 , 0.60]

Favours PFMT

Favours pessary

### Analysis 2.17. Comparison 2: Any pessary versus PFMT, Outcome 17: Cure or improvement of sexual problems at 24 months (measured with PISQ-12, range: 0-48, higher score = better sexual functioning)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Mean Pessary</th>
<th>SD</th>
<th>Total</th>
<th>Mean PFMT</th>
<th>SD</th>
<th>Total</th>
<th>Mean Difference IV, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panman 2016</td>
<td>35.7</td>
<td>5.1</td>
<td>34</td>
<td>36.7</td>
<td>4.5</td>
<td>24</td>
<td>-1.00 [-3.49 , 1.49]</td>
</tr>
</tbody>
</table>

Mean Difference IV, Fixed, 95% CI: -1.00 [-3.49 , 1.49]

Favours PFMT

Favours pessary
Analysis 2.18. Comparison 2: Any pessary versus PFMT, Outcome 18: Number of women with adverse events

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary</th>
<th>PFMT</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>Panman 2016</td>
<td>21</td>
<td>35</td>
<td>75.25 [4.70, 1205.45]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>21</td>
<td>35</td>
<td>75.25 [4.70, 1205.45]</td>
</tr>
<tr>
<td></td>
<td>62</td>
<td>62</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Comparison 3. Any pessary plus PFMT versus PFMT alone

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Perceived improvement of prolapse symptoms at 12 months</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3.2 Cure or improvement of bladder problems - SUI</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3.3 Cure or improvement of bladder problems - UUI</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3.4 Cure or improvement of bladder problems - voiding difficulty</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3.5 Number of women with adverse events - abnormal vaginal bleeding</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>3.6 Number of women with adverse events - de novo voiding difficulty</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Fixed, 95% CI)</td>
<td>Subtotals only</td>
</tr>
</tbody>
</table>

Analysis 3.1. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 1: Perceived improvement of prolapse symptoms at 12 months

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary plus PFMT</th>
<th>PFMT</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>M-H, Fixed, 95% CI</td>
</tr>
<tr>
<td>Cheung 2016</td>
<td>80</td>
<td>132</td>
<td>2.15 [1.58, 2.94]</td>
</tr>
</tbody>
</table>
### Analysis 3.2. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 2: Cure or improvement of bladder problems - SU1

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary plus PFMT</th>
<th>PFMT</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Cheung 2016</td>
<td>19</td>
<td>82</td>
<td>15</td>
<td>70</td>
</tr>
</tbody>
</table>

### Analysis 3.3. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 3: Cure or improvement of bladder problems - UUI

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary plus PFMT</th>
<th>PFMT</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Cheung 2016</td>
<td>17</td>
<td>59</td>
<td>18</td>
<td>44</td>
</tr>
</tbody>
</table>

### Analysis 3.4. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 4: Cure or improvement of bladder problems - voiding difficulty

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary plus PFMT</th>
<th>PFMT</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Cheung 2016</td>
<td>25</td>
<td>40</td>
<td>11</td>
<td>31</td>
</tr>
</tbody>
</table>

### Analysis 3.5. Comparison 3: Any pessary plus PFMT versus PFMT alone, Outcome 5: Number of women with adverse events - abnormal vaginal bleeding

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary plus PFMT</th>
<th>PFMT</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Cheung 2016</td>
<td>9</td>
<td>132</td>
<td>4</td>
<td>128</td>
</tr>
</tbody>
</table>

Test for subgroup differences: Not applicable
### Analysis 3.6. Comparison 3: Any pessary plus PFMT versus PFMT alone,
Outcome 6: Number of women with adverse events - de novo voiding difficulty

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Pessary plus PFMT</th>
<th>PFMT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
</tr>
<tr>
<td>Cheung 2016</td>
<td>10</td>
<td>92</td>
</tr>
</tbody>
</table>

Test for subgroup differences: Not applicable

### APPENDICES

**Appendix 1. Search of the Cochrane Incontinence Specialised Register**

The search terms used to search the Cochrane Incontinence Specialised Register are given below:

```
((design.cct* OR design.rct*))
AND
topic.prolapse*
AND
invent.mech*
```

All searches were of the keywords field of EndNote 2018.

**Appendix 2. Search methods and strategies for the extra specific searches conducted for some of the previous versions of this review**

**Electronic databases**

**MEDLINE** (January 1966 to Week 5 August 2005) was searched on 14 September 2005 and PREMEDLINE (15 September 2005) was searched on 19 September 2005, both on OVID, using the following search terms:

1. prolapse/
2. uterine prolapse/
3. Rectocele/
4. (prolaps$ adj5 (pelvi$ or vagin$ or genit$ or uter$ or vault$ or apical or urethr$ or segment$ or wall$)).tw.
5. cystoc?ele$.tw.
6. rectoc?ele$.tw.
7. urethroc?ele$.tw.
8. enteroc?ele$.tw.
10. sigmoidoc?ele$.tw.
11. (pelvi$ adj3 dysfunct$).tw.
12. (pelvi$ adj3 (disorder$ or relax$)).tw.
15. (cervi$ adj5 prolaps$).tw.
16.or/1-15

This set of terms was combined with the first two parts of the Cochrane Highly Sensitive Search Strategy for randomised controlled trials (Appendix 5b.2, Cochrane Handbook, version 4.2, March 2003) using the Boolean operator 'AND'.

**Embase** (January 1996 to Week 43 2005) was searched on 25 October 2005, on OVID, using the following search terms:

1. pelv adj5 prolaps$.tw.
2. uterus prolapse/
3. rectocele/
4. vagina prolapse/
5. cystocele/
6.or/1-5

---

**Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)**

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
7. randomised controlled trial/
8. controlled study/
9. clinical study/
10. major clinical study/
11. prospective study/
12. meta analysis/
13. exp clinical trial/
14. randomisation/
15. crossover procedure/ or double blind procedure/ or parallel design/ or single blind procedure/
16. placebo/
17. latin square design/
18. exp comparative study/
19. follow up/
20. pilot study/
21. family study/ or feasibility study/ or study/
22. placebo.tw.
23. random$tw.
25. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.
26. factorial.tw.
27. crossover.tw.
28. latin square.tw.
30. or/7-29
32. 30 not 31
33. 6 and 32

CINAHL (January 1982 to February Week 4 2003) was searched on 13 March 2003, on OVID, using the following search terms:

1. exp pelvic organ prolapse/
2. genital diseases, female/
3. prolapse/
4. uterine prolapse/
5. Rectocele/
6. (prolaps$ adj5 (pelvi$ or vagin$ or genit$ or uter$ or vault$ or apical or urethr$ or segment$ or wall$)).tw.
7. cystoc?ele$tw.
8. rectoc?ele$tw.
10. enteroc?ele$tw.
11. proctoc?ele$tw.
12. sigmoidoc?ele$tw.
14. (pelvi$ adj3 (disorder$ or relax$)).tw.
15. (vagin$ adj3 defect$).tw.
17. (cervi$ adj5 prolaps$).tw.
18. ((descen$ adj2 (uter$ or genit$ or pelv$)).tw.
19. procident$.tw.
20. (vagin$ adj2 (eversion$ or evert$)).tw.
21. (hernia$ adj2 (bladder$ or cystic or vesico$)).tw.
22. (bladder$ adj2 protru$).tw.
23. (viscer$ adj2 prolap$).tw.
24. hysteropex$tw.
25. or/1-2
26. placebo$tw.
27. random$tw.
29. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.
30. factorial.tw.
31. crossover.tw.
32. latin square.tw.
PEDro (the Physiotherapy Evidence Database) (url: www.pedro.fhs.usyd.edu.au) produced by the Centre for Evidence-Based Physiotherapy (CEBP), University of Sydney, Australia was searched on 13 October 2003 using the search term "prolapse".

The UK National Research Register (Issue 3, 2003), Controlled Clinical Trials (April 2003) and ZETOC database of conference abstracts (April 2003) were searched using the search terms cystocele, urethrocele, rectocele, vault prolapse, uterine prolapse, vaginal prolapse, pelvic organ prolapse, pelvic floor.

The reference lists of relevant articles were searched for other possibly relevant trials.

We did not impose any language or other restrictions on any of the searches.

Appendix 3. Search methods for the brief economic commentary (BEC)

We performed searches for the brief economic commentary (BEC). We searched:

- The NHS Economic Evaluation Database (NHS EED) on the Centre for Reviews and Dissemination (CRD) website (covering from the earliest record in NHS EED, dating from 1968, up to and including 31 December 2014 when their coverage ended). Date of search: 13 February 2020.

As NHS EED is no longer actively updated we performed additional searches of the following databases to identify eligible studies added to these databases from 1 January 2015 onwards (date of search: 13 February 2020):

- MEDLINE on OvidSP (covering 1 January 1946 to January February 1 2020); and
- Embase (on OvidSP) (covering 1 January 1974 to 2020 Week 06).

The economic evaluation search filters applied to our MEDLINE and Embase search strategies were those formerly used by the CRD to identify published reports of full economic evaluations for indexing on NHS EED. These economic evaluation search filters remain freely available on the CRD Database web-pages (CRD 2015). The other search lines in the MEDLINE and Embase search strategies were adapted from the electronic search strategies run for our Cochrane Incontinence Specialised Register along with additional terms for this population developed specifically for this review. Similarly, our NHS EED search strategy was adapted from search strategies run for our Specialised Register and based on textword and MeSH terms (capturing relevant P-I-C concepts) used to identify eligible studies of intervention effects. We followed the current economic methods guidance (Shemilt 2019).

Ovid MEDLINE(R) on OvidSP covering 1 January 1946 to January February 1 2020 was searched on 13 February 2020 using the following search strategy:

1. Economics/
   2. exp "costs and cost analysis"/
   3. Economics, Dental/
   4. exp economics, hospital/
   5. Economics, Medical/
   6. Economics, Nursing/
   7. Economics, Pharmaceutical/
   8. (economic$ or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic$).ti,ab.
   9. (expenditure$ not energy).ti,ab.
   10. value for money.ti,ab.
   11. budget$.ti,ab.
   12. or/1-11
   13. ([energy or oxygen] adj cost).ti,ab.
15. ((energy or oxygen) adj expenditure).ti,ab.
16. or/13-15
17. 12 not 16
18. letter.pt.
19. editorial.pt.
20. historical article.pt.
21. or/18-20
22. 17 not 21
23. exp animals/ not humans/
24. 22 not 23
25. prolapse/
26. uterine prolapse/
27. Rectocele/
28. (prolaps$ adj5 (pelvi$ or vagin$ or genit$ or uter$ or vault$ or apical or urethr$ or segment$ or wall$)).tw.
29. cystoc?ele$.tw.
30. rectoc?ele$.tw.
31. urethroc?ele$.tw.
32. enteroc?ele$.tw.
33. proctoc?ele$.tw.
34. sigmoidoc?ele$.tw.
35. (pelvi$ adj3 dysfunct$).tw.
36. (pelvi$ adj3 (disorder$ or relax$)).tw.
37. (vagin$ adj3 defect$).tw.
40. exp Pelvic Organ Prolapse/
41. Pelvic Floor/
42. Pelvic Floor Disorders/
44. perineomet$.tw.
45. (prolaps$ adj5 rect$).tw.
46. or/25-45
47. 24 and 46

Embase on OvidSP covering 1 January 1974 to 2020 Week 06 was searched on 13 February 2020 using the following search strategy:

1. Health Economics/
Pessaries (mechanical devices) for managing pelvic organ prolapse in women (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
37. (prolaps$ adj5 rect$).tw.
38. cystoc$ele$.tw.
39. rectoce$ele$.tw.
40. urethroc$ele$.tw.
41. enteroc$ele$.tw.
42. proctoc$ele$.tw.
43. sigmoidoc$ele$.tw.
44. (pelvi$ adj3 dysfunct$).tw.
45. (pelvi$ adj3 (disorder$ or relax$)).tw.
46. (vagin$ adj3 defect$).tw.
47. (urogenital adj5 prolap$).tw.
48. (cervi$ adj5 prolap$).tw.
49. (pelvi$ adj2 floor).tw.
50. perineomet$.tw.
51. pelvis floor/
52. or/32-51
53. 31 and 52

**NHS EED** on the Centre for Reviews and Dissemination (CRD) website (covering from the earliest record in NHS EED, dating from 1968, up to and including 31 December 2014 when their coverage ended). Date of search: 13 February 2020. The search strategy used is given below.

<table>
<thead>
<tr>
<th>Search</th>
<th>Hits</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>(MeSH DESCRIPTOR Prolapse EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>2</td>
<td>(MeSH DESCRIPTOR Cystocele EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>3</td>
<td>(MeSH DESCRIPTOR Pelvic Organ Prolapse EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>4</td>
<td>(MeSH DESCRIPTOR Rectal Prolapse EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>5</td>
<td>(MeSH DESCRIPTOR Uterine Prolapse EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>6</td>
<td>(MeSH DESCRIPTOR Visceral Prolapse EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>7</td>
<td>(MeSH DESCRIPTOR Rectocele EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>8</td>
<td>(MeSH DESCRIPTOR Pelvic Floor EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>9</td>
<td>(MeSH DESCRIPTOR Pelvic Floor Disorders EXPLODE ALL TREES) IN NHSEED</td>
</tr>
<tr>
<td>10</td>
<td>((pelvi* ADJ5 prolap$)) OR ((prolaps* ADJ5 pelvi*)) IN NHSEED</td>
</tr>
<tr>
<td>11</td>
<td>((vagin* ADJ5 prolap$)) OR ((prolaps* ADJ5 vagin*)) IN NHSEED</td>
</tr>
</tbody>
</table>
((genit* ADJ5 prolaps*)) OR ((prolaps* ADJ5 genit*)) IN NHSEED

((uter* ADJ5 prolaps*)) OR ((prolaps* ADJ5 uter*)) IN NHSEED

((vault* ADJ5 prolaps*)) OR ((prolaps* ADJ5 vault*)) IN NHSEED

((apical ADJ5 prolaps*)) OR ((prolaps* ADJ5 apical)) IN NHSEED

((urethr* ADJ5 prolaps*)) OR ((prolaps* ADJ5 urethr*)) IN NHSEED

((segment* ADJ5 prolaps*)) OR ((prolaps* ADJ5 segment*)) IN NHSEED

((wall* ADJ5 prolaps*)) OR ((prolaps* ADJ5 wall*)) IN NHSEED

((rect* ADJ5 prolaps*)) OR ((prolaps* ADJ5 rect*)) IN NHSEED

((urogen* ADJ5 prolaps*)) OR ((prolaps* ADJ5 urogen*)) IN NHSEED

((cervi* ADJ5 prolaps*)) OR ((prolaps* ADJ5 cervi*)) IN NHSEED

((pelvi* ADJ5 dysfunct*)) OR ((dysfunct* ADJ5 pelvi*)) IN NHSEED

((pelvi* ADJ5 disorder*)) OR ((disorder* ADJ5 pelvi*)) IN NHSEED

((pelvi* ADJ5 relax*)) OR ((relax* ADJ5 pelvi*)) IN NHSEED

((pelvi* ADJ5 floor*)) OR ((floor* ADJ5 pelvi*)) IN NHSEED

((vagin* ADJ5 defect*)) OR ((defect* ADJ5 vagin*)) IN NHSEED

(perineomet*) IN NHSEED

(cystocele*) OR (cystocoele*) IN NHSEED

(rectocele*) OR (rectocele*) IN NHSEED

(urethrocele*) OR (urethrocoele*) IN NHSEED

(enterocele*) OR (enteroceles*) IN NHSEED

(proctocele*) OR (proctocele*) IN NHSEED

(sigmoidocele*) OR (sigmoidocoele*) IN NHSEED

#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33

**WHAT'S NEW**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 November 2020</td>
<td>New search has been performed</td>
<td>The following changes were made for this update, published in 2020.</td>
</tr>
</tbody>
</table>
1. We updated the search to January 2020 and included a total of four trials (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016). The crossover study included in the previous version of the review has been excluded due to concerns about carry-over data with this study design.

2. We amended the outcomes to reflect those that are most important to women and to clinical decision-makers. We presented separate outcomes for resolution of prolapse symptoms and improvement in prolapse and we also included as an outcome the number of women with adverse events.

3. We removed two comparisons due to their lack of contribution to the evidence base regarding the effectiveness of pessaries as a treatment: pessary plus another treatment versus pessary alone; and differing frequencies of pessary device review or device change.

4. We conducted and included a brief economic commentary to summarise the principal findings of full economic evaluations that compared pessaries with alternative treatment interventions for pelvic organ prolapse in women.

5. We substantially modified the methodology of the review in accordance with current Cochrane guidance, including adding ‘Summary of findings’ tables and assessing the certainty of the body of evidence using the GRADE approach.

6. The authorship of the review has changed.

HISTORY

Protocol first published: Issue 1, 2003
Review first published: Issue 2, 2004

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 August 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
<tr>
<td>26 January 2006</td>
<td>New search has been performed</td>
<td>Minor update: 26/01/06 New studies sought but none found: 26/10/05</td>
</tr>
<tr>
<td>25 February 2004</td>
<td>New citation required and conclusions have changed</td>
<td>Review first published</td>
</tr>
</tbody>
</table>

CONTRIBUTIONS OF AUTHORS

CB: reviewed abstracts, extracted data and produced the final review.
EJA: contributed to writing the final review and arbitrated on inclusion/extraction decisions.
DG: reviewed abstracts and contributed to writing the final review.
FS: supported abstract review and data extraction and contributed to writing the final review.
MD: reviewed abstracts and extracted data and contributed to writing the final review  
PS: conducted the brief economic commentary  
RK: extracted data and contributed to writing the final review.

DECLARATIONS OF INTEREST

In accordance with Cochrane's Commercial Sponsorship Policy, the following interests are declared.

CB: none known  
EJA: none known  
DG: Travel and accommodation expenses provided by Boston Scientific to attend the International Urogynaecology Association's annual conference in Lisbon in 2011. Expenses were paid into the Urogynaecology Department Endowment Fund at the Central Manchester University Hospitals NHS Foundation Trust.  
FS: none known  
MD: none known  
PS: none known  
RK: none known

SOURCES OF SUPPORT

Internal sources
- No sources of support supplied

External sources
- National Institute of Health Research, UK

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to Cochrane Incontinence. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Evidence Synthesis Programme, the NIHR, NHS or the Department of Health and Social Care.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

For this update, published in 2020, we made the following changes.

1. We updated the search to January 2020 and included a total of four trials (Baessler 2019; Cheung 2016; Coolen 2018; Panman 2016). The crossover study included in the previous version of the review (Bugge 2013b) has been excluded due to concerns about carry-over data with this study design.

2. We amended the outcomes to reflect those that are most important to women and to clinical decision-makers. We presented separate outcomes for resolution of prolapse symptoms and improvement in prolapse and we also included as an outcome the number of women with adverse events.

3. We removed two comparisons due to their lack of contribution to the evidence base regarding the effectiveness of pessaries as a treatment: pessary plus another treatment versus pessary alone; and differing frequencies of pessary device review or device change.

4. We conducted and included a brief economic commentary to summarise the principal findings of full economic evaluations that compared pessaries with alternative treatment interventions for pelvic organ prolapse in women.

5. We substantially modified the methodology of the review in accordance with current Cochrane guidance, including adding 'Summary of findings' tables and assessing the certainty of the body of evidence using the GRADE approach.

INDEX TERMS

Medical Subject Headings (MeSH)
- Pelvic Organ Prolapse [*therapy]; *Pessaries; Randomized Controlled Trials as Topic; Rectal Prolapse [*therapy]; Urethral Diseases [therapy]; Urinary Bladder Diseases [therapy]; Uterine Prolapse [therapy]

MeSH check words
- Female; Humans